



MIR-744 MODULATION BY DISTURBED FLOW AND ITS ROLE 














In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 
Wallace H. Coulter Department of Biomedical Engineering 
 
 
Georgia Institute of Technology 
December 2017 
 




MIR-744 MODULATION BY DISTURBED FLOW AND ITS ROLE 









Approved by:   
   
Dr. Hanjoong Jo, Advisor 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
 Dr. Loren Williams 
School of Chemistry & Biochemistry 
Georgia Institute of Technology 
 
Dr. Michael Davis 
School of Biomedical Engineering 
Georgia Institute of Technology 
 Dr. Charles Searles 
School of Medicine, Division of Cardiology 
Emory University 
 
Dr. Younan Xia 
School of Biomedical Engineering 
Georgia Institute of Technology 
 
  





 First of all, I would like to thank everyone on my thesis committee for reading this 
document! Thank you Dr. Xia for collaborating with us in the past, as well as writing all 
the reference letters and providing insight into all my projects as a whole! Thank you Dr. 
Williams for asking very insightful questions and sparking discussion during committee 
meetings. Furthermore, thank you for your suggestions on how to best present my work! 
Thank you Dr. Searles for providing an expertise in miRNAs and a clinical perspective to 
better this work. Thank you Dr. Davis for providing your expertise in cardiovascular 
biology, as well as helpful tips for how to best quantify the data. Furthermore, I would like 
to especially thank my advisor, Dr. Jo, for providing his insight into all aspects of the 
project, including data acquisition, analysis, and how best to present the data at the end. 
The combined expertise of my thesis committee allowed me to identify the most critical 
experiments and interpret their findings in the broader scheme of cardiovascular disease.  
 Thank you to my former lab mates Inhwan, Chanwoo, Jessie, and Jack for the 
excellent conversations and help with experiments. Also thank you Dong won and Sunkum 
for help with the mouse studies and general lab support. Thank you to all of my current lab 
mates as well, including Marwa,  Joan, Sanjoli, Cat, Darian, and Nico. I would also like to 
thank our “neighbors” the Davis Lab, especially Srishti for reagents and the wonderful 
chats!  
 Finally, I would especially like to thank my family Pam, Crystal, Alyssa, and Jacob 
for everything as well as friends such as Layla and Aras, Farnaz, and Subin for all of their 




TABLE OF CONTENTS 
ACKNOWLEDGEMENTS ............................................................................................... iii 
 
LIST OF FIGURES ......................................................................................................... viii 
 
LIST OF TABLES ...............................................................................................................x 
 
LIST OF ABBREVIATIONS ............................................................................................ xi 
 
SUMMARY ...................................................................................................................... xii 
 
1 CHAPTER 1 INTRODUCTION ..................................................................................1 
 Vascular Fluid Mechanics and Hemodynamics in the Arteries ............................1 
 Atherosclerosis and Localization of Plaques ........................................................2 
 Endothelial Regulation by Flow ...........................................................................4 
 Models of Flow and Shear Stress to Study Endothelial Function and 
Atherosclerosis ................................................................................................................ 6 
1.4.1 In vitro  Models of Shear Stress ....................................................................6 
1.4.2 In vivo  Models of Shear Stress and Atherosclerosis .....................................7 
 Mechanosensing and Mechanotransduction in Atherosclerosis ...........................8 
1.5.1 Mechanosensors .............................................................................................8 
1.5.2 Mechanosensitive Signaling Pathways ........................................................15 
 MicroRNAs and Atherosclerosis ........................................................................21 
1.6.1 Biogenesis of miRNAs ................................................................................21 
1.6.2 Mechanosensitive Endothelial-Derived miRNAs in Atherosclerosis ..........22 
1.6.3 miRNA Animal Studies in Atherosclerosis .................................................26 
1.6.4 miRNAs in the Clinic ..................................................................................28 
1.6.5 TSB Studies .................................................................................................30 
 MicroRNA miR-744 in Disease Development and Implications for 
Atherosclerosis .............................................................................................................. 32 
 LIMS2/PINCH2 ..................................................................................................33 
v 
 
 ILK Signaling, Focal Adhesions, and Atherosclerosis .......................................34 
 
2 CHAPTER 2 SPECIFIC AIMS AND HYPOTHESES .............................................37 
 Significance and Impact ......................................................................................37 
 Rationale .............................................................................................................37 
 Innovation ...........................................................................................................38 
 Project Objective .................................................................................................39 
 Overall Hypothesis ..............................................................................................39 
 Specific Aim I: Demonstrate the Mechanosensitivity of miR-744 and Its Role in 
EC Inflammation ............................................................................................................40 
 Specific Aim II: Determine the Direct Targets of miR-744 and Their Role in EC 
Inflammation ..................................................................................................................41 
 Specific Aim III:  Determine the Role of miR-744 in the Development of 
Atherosclerosis .............................................................................................................. 42 
 
3 CHAPTER 3 MATERIALS AND METHODS .........................................................43 
 Cell Culture and Shear Experiments ...................................................................43 
3.1.1 HUVECs ......................................................................................................43 
3.1.2 HAECs .........................................................................................................43 
3.1.3 iMAECs .......................................................................................................44 
3.1.4 Cone and Plate Viscometer ..........................................................................44 
 Partial Carotid Ligation and Lesser Curvature Endothelial RNA Isolation ........45 
3.2.1 Partial Carotid Ligation and Endothelial Flushing ......................................45 
3.2.2 Lesser Curvature and Greater Curvature Endothelial RNA Isolation .........45 
 Quantitative real-time PCR (qPCR) Validation of miR-744 ..............................46 
 Transfection of Nucleic Acids ............................................................................47 
 Monocyte Adhesion Assay .................................................................................47 
 qPCR for Inflammatory Markers ........................................................................48 
 BCA and Western Blotting for Inflammatory Markers ......................................49 
 P65 Staining ........................................................................................................50 
 Ago2 Immunoprecipitation and RNA Sequencing .............................................51 
 Filtration Criteria .................................................................................................51 
 qPCR for Potential Targets .................................................................................52 
 3’UTR Luciferase Assay .....................................................................................53 
 Immunofluorescence Staining .............................................................................54 
vi 
 
 Human Plaque De-paraffinization and Immunostaining ....................................54 
 Partial Carotid Ligation and AntimiR-744 Injection ..........................................54 
 Oil Red O Staining ..............................................................................................55 
 RNA Extraction from Organs and qPCR ............................................................55 
 Immunofluorescence Staining .............................................................................56 
 Hematoxylin and Eosin Staining .........................................................................56 
 TSB Design and Transfection .............................................................................57 
 Partial Carotid Ligation and TSB Injection ........................................................57 
 Statistical Analysis ..............................................................................................58 
 
4 CHAPTER 4 AIM I: MIR-744 IS INDUCED BY DISTURBED FLOW AND 
INDUCES ENDOTHELIAL INFLAMMATION ............................................................ 59 
 Summary .............................................................................................................59 
 Results .................................................................................................................60 
4.2.1 miR-744 Shares a Seed Sequence with miR-663 and is Induced by OS in 
Human ECs ................................................................................................................ 60 
4.2.2 miR-744 is Induced by D-flow in Mice both in vitro and in vivo ...............61 
4.2.3 miR-744 Modulates Endothelial Inflammation in human ECs ...................62 
4.2.4 miR-744 Modulates Endothelial Inflammation in Mouse ECs ...................64 
 Discussion ...........................................................................................................65 
 
5 CHAPTER 5 AIM II: MIR-744 MEDIATES ENDOTHELIAL INFLAMMATION 
VIA LIMS2 ....................................................................................................................... 70 
 Summary .............................................................................................................70 
 Results .................................................................................................................71 
5.2.1 Sequencing of Ago2-Immunoprecipitated RNAs and Sequencing Reveals 
13 Conserved Targets .................................................................................................71 
5.2.2 Target Screening Reveals LIMS2 is a mechanosensitive target of miR-744 
in HUVECs .................................................................................................................73 
5.2.3 LIMS2 Identified as Conserved Target in Humans and Mice .....................76 
5.2.4 LIMS2 is Lost in Advanced Lesions in Human Patients .............................78 
5.2.5 LIMS2 Silencing Induces Endothelial Inflammation ..................................79 




6 CHAPTER 6 AIM III: TARGETING THE LIMS2-744 AXIS INHIBITS 
ATHEROSCLEROSIS PROGRESSION ......................................................................... 84 
 Summary .............................................................................................................84 
 Results .................................................................................................................85 
6.2.1 AntimiR-744 Treatment Does Not Reduce Plaque .....................................85 
6.2.2 AntimiR-744 Did not Rescue LIMS2 Expression in the Carotids ..............87 
6.2.3 TSBs Rescue LIMS2 and Prevent VCAM1 Expression in iMAECs ..........88 
6.2.4 LIMS2 TSBs Significantly Reduce Plaque Burden, Arterial Diameter, and 
VCAM1 Staining in Mice .......................................................................................... 89 
6.2.5 LIMS2 TSBs Significantly Rescued LIMS2 Expression ............................91 
6.2.6 Binding Partners ILK and PINCH1 are Shear Sensitive and Regulated by 
siLIMS2 and Mimic................................................................................................... 92 
 Discussion ...........................................................................................................94 
 
7 CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS ...............................97 
 Conclusions .......................................................................................................106 
 Future Directions ...............................................................................................106 
 
APPENDIX ......................................................................................................................109 
A.1. List of Genes Differentially Enriched in Ago2 Immunoprecipitation ..............109 






LIST OF FIGURES 
Figure 1.1 Hemodynamic Forces on the Artery Wall. ........................................................ 1 
Figure 1.2 Stages of Atherosclerosis. ................................................................................. 3 
Figure 1.3 Models Of Flow And Shear Stress. ................................................................... 8 
Figure 1.4 The Endothelial Cell Senses Shear Stress Through Mechanosensors. ............ 15 
Figure 1.5 Shear Stress Leads To The Activation Of Multiple Intracellular Pathways. .. 20 
Figure 1.6 Biogenesis of miRNAs. ................................................................................... 22 
Figure 1.7 Role Of Mechanosensitive miRNAs In Atherosclerosis. ................................ 26 
Figure 3.1 LS Aligns Endothelial Cells ............................................................................ 44 
Figure 3.2 The Lesser Curvature is Chronically Flow-Disturbed ..................................... 46 
Figure 3.3 AntimiR-744 Injection Schedule ..................................................................... 55 
Figure 3.4 LIMS2 TSB Injection Schedule ...................................................................... 57 
Figure 4.1 miR-744 shares A Seed Sequence With miR-663 and Is Induced by OS in 
Human ECs. ...................................................................................................................... 60 
Figure 4.2 miR-744 is induced by D-flow in mice both in vitro and in vivo. .................. 61 
Figure 4.3 miR-744 Modulates Endothelial Inflammation In Human ECs. ..................... 63 
Figure 4.4 miR-744 Modulates Endothelial Inflammation in iMAECs. .......................... 64 
Figure 4.5 miR-663 and miR-744 Copies Vary in HUVECs, HAECs, and iMAECs. ..... 66 
Figure 4.6 miR-744 Copies Vary In The Carotids and In The Aortic Arches Of Mice. .. 67 
Figure 4.7 miR-744 Modulates Migration and Proliferation in Human ECs. .................. 69 
Figure 5.1 RNA Sequencing Reveals 13 Potential miR-744 Targets. .............................. 72 
ix 
 
Figure 5.2 LIMS2 Emerges as a Consistent, Mechanosensitive Target of miR-744 in 
HUVECs. .......................................................................................................................... 75 
Figure 5.3 LIMS2 is a Mechanosensitive, Conserved Target of miR-744. ...................... 77 
Figure 5.4 LIMS2 is Lost in Atherosclerosis. ................................................................... 78 
Figure 5.5 LIMS2 Silencing Induces Endothelial Inflammation In Human ECs. ............ 79 
Figure 5.6 LIMS2 Copy Number is Higher in Arterial Endothelium. .............................. 83 
Figure 6.1 AntimiR-744 Did Not Reduce Plaque in the Acute, Partial Carotid Ligation 
Model of Atherosclerosis. ................................................................................................. 86 
Figure 6.2 AntimiR-744 Rescued LIMS2 in the Spleen, but not in the Carotids. ............ 87 
Figure 6.3 TSBs Rescue LIMS2 and Decrease VCAM1 Expression. .............................. 88 
Figure 6.4 LIMS2 TSBs Significantly Reduce Plaque Burden and VCAM1 Expression. 90 
Figure 6.5 LIMS2 TSBs Significantly Rescued LIMS2 ................................................... 91 
Figure 6.6 LIMS2 Modulates ILK and PINCH1 Expression. .......................................... 93 





LIST OF TABLES 
Table 3.1 Primer Sequences for qPCR of Inflammatory Markers .................................... 48 
Table 3.2 List of Inflammatory Marker Antibodies .......................................................... 50 
Table 3.3 List of Primers for qPCR of Potential Target Genes ........................................ 52 
Table 3.4 List of Antibodies for Immunostaining ............................................................ 56 
Table A.1 List of Genes Differentially Enriched in Ago2 Immunoprecipitation……….109 






















LIST OF ABBREVIATIONS 
d-flow   Disturbed flow   TSB Target Site Blocker 
OS   Oscillatory shear stress  PCL Partial Carotid Ligation 
miRNA  MicroRNA    LC  Lesser Curvature         
HUVECs  Human Umbilical Vein ECs  S.C.  subcutaneous injection 
HAECs Human Aortic ECs 
iMAECs immortalized Mouse Aortic ECs 
TGFβ1   Transforming Growth Factor 
ECs   Endothelial Cells 
PCL   Partial Carotid Ligation 
ApoE   Apolipoprotein E 
LNA   Locked Nucleic Acid 
LDL   Low Density Lipoprotein 
LS   Laminar shear stress 
LCA   Left Carotid Artery 
RCA   Right Carotid Artery 
S-flow   stable, unidirectional flow 
KLF2   Kruppel Like Factor  
VCAM1  Vascular Cell Adhesion Molecule 
eNOS   endothelial Nitric Oxide Synthase 
MMP   Matrix Metalloproteinase 
NFkB   Nuclear Factor k B 
UTR   Untranslatable Region 
Ago2   Argonaute 2 
RISC   RNA-Induced Silencing Complex 
TA   Thoracic Aorta 




 Atherosclerosis is a disease of chronic inflammation affecting the vascular wall of 
larger arteries. Atherogenesis is the main cause of myocardial infarction, ischemic stroke 
and peripheral arterial disease, however, the underlying molecular mechanisms are still 
incompletely understood. D-flow is known to regulate endothelial cell function via a 
process known as mechanotransduction. The mechanisms by which d-flow induces pro-
atherogenic responses predominantly involve endothelial gene expression, including 
differential microRNA (miRNA) expression.  
miRNAs are a large class of evolutionarily conserved, noncoding RNAs which 
function as  post-transcriptional regulators by interacting with the 3’ untranslated region 
(3’ UTR) of specific target mRNAs in a sequence-specific manner [1]. It is thought that a 
single miRNA can target hundreds of mRNAs. These miRNAs negatively regulate gene 
expression through translational repression or mRNA cleavage, depending on the degree 
of complementarity. The majority of flow sensitive miRNAs have been characterized in 
vitro. Therefore, only a limited number of direct links to atherosclerosis have been 
established [2].  
 In previous studies by our group, the primate-specific miRNA, miR-663, was 
identified as a shear-sensitive miRNA involved in endothelial inflammation [3]. Despite 
these findings, as it is not conserved in mice, animal studies could not be conducted.  
However, we found that miR-744 is conserved across mammalian species and shares a seed 
sequence with miR-663. Finally, miR-744 is highly expressed in patients with heart failure, 
thus implicating the relevance of this miRNA to cardiovascular pathologies. Therefore, our 
overall hypothesis is that overexpression of the miR-744 in disturbed flow regions causes 
suppression of key target genes that promote endothelial homeostasis, thus tipping the 
balance towards endothelial inflammation and atherosclerosis.  
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 The goal of this project was to elucidate the effects of d-flow-induced miR-744 on 
endothelial gene expression and the mechanisms initiating endothelial inflammation and 
atherosclerosis. To test the hypothesis, miR-744 modulation of OS-induced endothelial 
inflammation was assessed in vitro, direct targets of miR-744 were established in vitro, and 
the therapeutic effect of miR-744 inhibition on atherosclerosis development was assessed 
in vivo.  
 In Aim 1, we found that miR-744 is upregulated by OS in both human and murine 
endothelial cells, the acutely flow disturbed LCA, and the chronically flow disturbed lesser 
curvature (LC). Furthermore, we found that supplementation of miR-744 by mimics 
increases monocyte adhesion as well as multiple inflammatory cell adhesion molecules 
such as VCAM1, ICAM1, MCP-1, and p65. Finally, inhibition of miR-744 by an LNA-
based antimiRNA (antimiR) can reduce OS-induced expression of these same 
inflammatory markers.  
 In Aim 2, we discovered by sequencing mRNAs directly bound to Ago2 in RISC 
specific targets of miR-744 in ECs. We filtered these targets based on conservation 
between species and through multiple validation steps, we found that LIMS2 is a conserved 
target of miR-744. Furthermore, we studied LIMS2 and found that LIMS2 silencing itself 
promotes endothelial inflammation via siRNA.  
Finally, in Aim 3, we found that although global inhibition of miR-744 did not 
significantly inhibit atherosclerosis progression, inhibition of the specific interaction of 
mIR-744 and LIMS2 by TSBs showed a reduction in plaque. The work presented here has 
resulted in the discovery of a novel, shear-sensitive miRNA, a novel, shear-sensitive gene, 
and underscores the importance of the specificity of the miRNA-gene interaction. Finally, 
we found that LIMS2 binds to the well-known integrin-linked kinase (ILK), which may 
explain its role in inflammation. This work also provides a foundation for future studies to 
develop more targeted therapeutic strategies for CVD.
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CHAPTER 1 INTRODUCTION 
 Vascular Fluid Mechanics and Hemodynamics in the Arteries 
 The basic arterial wall structure consists of three layers: the innermost intimal layer 
comprised of the endothelium, the middle medial layer mainly comprised of smooth muscle 
cells, and the outermost adventitial layer, comprised of fibroblastic cells. The endothelium 
is a monolayer of cells which function as the barrier between the blood and the rest of the 
vessel wall, as well as a surface to resist blood clotting. Smooth muscle cells mainly act as 
the mechanical strength needed to support blood pressure-induced stretch. The forces 
experienced by the arterial wall include the normal stress of blood pressure induced by 
blood flow, the circumferential stretch induced by cyclic strain driven by the pressure 
pulse, and the wall shear stress exerted by the blood flowing tangential to the surface of 
the blood vessel. Wall shear stress (WSS), the frictional force between the blood and the 
endothelium, has emerged as a major determinant of endothelial function and gene 
expression. Thus, the focus of this thesis is the effect of wall shear stress on the 











Figure 1.1 Hemodynamic Forces on the Artery Wall.   
The blood vessel wall is comprised of the intimal, medial, and adventitial layers. The 
forces experienced by the arterial wall include the normal stress of blood pressure 
induced by blood flow, the circumferential stretch induced by cyclic strain driven by 
the pressure pulse, and the wall shear stress exerted by the blood flowing tangential 
to the surface of the blood vessel. Adapted from Tarbell et al. (2014) 
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 Atherosclerosis and Localization of Plaques 
 Although atherosclerosis is the most common cause of death in the world [1] and 
thus is widely studied, it is a complex disease and the mechanisms by which it occurs are 
still being elucidated. What is known is that atherosclerosis is an inflammatory disease 
occurring in the arterial wall. Atherosclerosis is initiated by inflammation in the endothelial 
layer, which allows the endothelium to become more permeable. After the barrier of the 
endothelium is compromised, bloodborne lipids such as those associated with low density 
lipoproteins (LDL), accumulate under in the intima. Once these lipids are present, immune 
cells, particularly monocytes, transmigrate into the intima as well with the aid of the 
endothelium and upon contact with the LDL, become foam cells to create lesions. These 
initial lesions then become progressively larger with age. The lesions, or plaques, are what 
characterizes atherosclerosis [2].  
 It is generally regarded that there are distinct stages of plaque progression. In brief, 
these include LDL accumulation in the intima, oxidation by resident macrophages and 
smooth muscle cells, recruitment of circulating monocytes by cytokines and transmigration 
by binding to endothelial cell adhesion molecules, foam cell formation, smooth muscle 
migration to the intimal layer, smooth muscle proliferation, and finally the formation of a 
necrotic core. Although plaques can be heterogeneous in nature, the consequences of 
plaque formation end in occlusion of the artery and a loss of blood flow and oxygen to 
downstream regions and organs. This can occur by either the development of a large, 
occlusive plaque, or a smaller, vulnerable plaque which erodes so that the endothelium is 





















 Interestingly, it has been observed that atherosclerotic plaques develop in specific 
regions of the vasculature. Specifically, as early as the 1960s, it was observed that plaques 
develop at sites of curvature, branching, or cross-sectional expansion and these sites 
experience flow separation [6]. At these regions, the flow departs from pulsatile, 
unidirectional flow to create flow-separation zones including flow reversal, oscillatory 
flow, and turbulence [7-10].  These sites include the abdominal aorta, the carotid 
bifurcation, and the lesser curvature of the aorta  [6]. However, Caro and colleagues were 
the first to show that lesions develop directly upstream of these flow dividers in regions of 
low wall shear stress [11, 12]. Following this initial study, Caro and Nerem perfused the 
common carotid arteries of dogs and studied cholesterol uptake, which is one of the 
initiating steps of atherosclerosis [13]. They found that the uptake of lipids in arteries could 
not be correlated with fluid phase mass transport rates, which lead the investigators to 
conclude that the blood flow directly on the arterial wall affected the cholesterol transport. 
In conjunction with Caro’s initial study, the hypothesis that atherosclerosis is localized to 
Figure 1.2 Stages of Atherosclerosis. The development of an atherosclerotic plaque 
initiates with LDL infiltration into the subendothelium, where it is oxidized by 
macrophages and smooth muscle cells, resulting in the conversion of macrophages to 
foam cells (1 and 2). The release of growth factors and cytokines by the resultant 
dysfunctional endothelium attracts additional monocytes (3 and 4). Foam cell 
accumulation and smooth muscle cell proliferation result in the growth of the plaque 
(6-8). Adapted from Faxon et al. (2004) 
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areas of low wall shear stress due to its effect on the arterial wall was validated by many 
other investigators [14-20]. Particularly, Ku and colleagues noted that not only is low wall 
shear stress an indicator of a site of plaque development, but also in these regions there is 
a reversal of the flow during the pulsatile flow cycle. Taken together, the flow pattern 
associated with atherosclerotic plaques corresponds to low, oscillating, shear stress 
known as disturbed flow (d-flow or OS). 
 Endothelial Regulation by Flow 
 Although Caro and Nerem found that the direct flow of fluid on the arterial wall 
affected cholesterol transport, it was not shown until later that the endothelium was 
involved. The direct effect of fluid flow on endothelial cells (ECs) was first demonstrated 
by Nerem and Dewey independently [21, 22]. In these studies, these investigators found 
that ECs align in the direction of flow. Later, Frangos et al. and Grabowski et al. observed 
that application of shear stress to static cells rapidly induced the antithrombotic 
prostacyclin [23, 24]. Furthermore, Mo et al. and Shen et al. independently found that shear 
transiently induces release of intracellular Ca2+, which acts as a signaling molecule [25, 
26]. Finally, Kuchan et al. and Korenaga et al. found that shear induces sustained release 
of the vasodilator nitric oxide (NO) [27-29]. Taken together, these studies on cultured ECs 
suggested that fluid shear stress directly affects the phenotype of ECs.   
 The main functions of the endothelium are to maintain a barrier between the blood 
and underlying tissues, regulation of vascular tone, recruitment of immune cells to sites of 
injury, and to form new blood vessels. Numerous studies have shown that each of these 
endothelial functions is greatly impacted by shear stress. One of the earliest functions to be 
studied was endothelial permeability as described above (Caro and Nerem), as well as 
further studies into the effects on individual transport pathways (tight junctions, adherens 
junctions, vesicles, and leaky junctions[13]. Specifically, endothelial permeability 
increases after the onset of shear stress, but decreases after prolonged exposure [30, 31]. 
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Furthermore, it was found that the biphasic response of endothelial permeability is due to 
increases in NO production from shear stress, which decrease permeability [32-34]. Taken 
together, these studies suggest that the acute increase in permeability is most relevant to 
the microcirculation, which responds to needs of specific organs, whereas the chronic 
response, which is downregulation of permeability due to sustained shear, are protective 
against the formation of atherosclerosis in that LDL is not allowed to penetrate the wall 
[35]. Furthermore, it has been shown in a mouse model of atherosclerosis that endothelial 
permeability is increased in atheroprone regions due to the degradation of the endothelial 
extracellular matrix (ECM) by matrix metalloproteinases (MMPs) [36]. Additionally, 
alterations in the endothelial ECM lead to stiffening of the intimal layer, which also affects 
endothelial permeability [37]. Not only does d-flow negatively impact endothelial 
permeability and ECM integrity and stiffness, it has also been shown to increase migration 
and angiogenesis [38, 39].   
Due to the effects of flow on the endothelium, it is unsurprising that several studies 
have found that there are site-specific changes in the endothelium at plaque-prone regions, 
particularly at curves, branches, and bifurcations. Numerous studies have shown that 
monocyte adhesion to the endothelium has been enhanced in these regions due to the 
presence of increased chemoattractants and adhesion molecules [40-42]. Furthermore, 
endothelial transcription profiles taken in these d-flow regions from mice [43] and pigs 
[44] indicate that in general, ECs exhibit a pro-inflammatory phenotype when exposed to 
d-flow. Hajra et al. found that the subunits of the pro-inflammatory nuclear transcription 
factor NFκB (p65, IκBα, IκBβ) were upregulated in areas of the proximal aortas of mice 
which were prone to lesion formation [43]. NFκB was only activated in a minority of the 
cells basally, but was highly activated when stimulated with LPS or hypercholesterolemia. 
Later, Passerini et al. found that in ECs isolated from either the inner aortic arch of pigs, 
which experiences d-flow, vs. the descending thoracic aorta, which experiences 
unidirectional laminar flow/laminar shear stress (LS), there was a general upregulation of 
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several inflammatory cytokines and NFκB elements [44]. Furthermore, in cells isolated 
from the thoracic aorta expressed more antioxidative genes, which are generally less 
inflammatory. Taken together, these studies indicated that the endothelium in these regions 
has a pro-inflammatory phenotype. Overall, disturbed blood on endothelium induces 
pro-inflammatory changes that impact endothelial leakiness, stiffness, and the ability 
to form new vessels. 
 Models of Flow and Shear Stress to Study Endothelial Function and 
Atherosclerosis 
1.4.1 In vitro Models of Shear Stress 
 There are a variety of in vitro and in vivo models to study the effects of d-flow on 
the endothelium specifically, as well as atherosclerosis (summarized in Figure 1.3 ). One 
of the first and most characterized in vitro models of shear stress is the cone-and-plate 
viscometer [22, 45]. In this system, shear stress is applied to cultured cells in a stationary 
plate by a rotating cone. A modified version was later introduced [46], which included a 
speed-controlled motor with variable rotational velocities. More recently, our lab has 
developed a modified cone-and-plate which is housed in a standard incubator and 
programmed shear stress profiles can be controlled by computer [47, 48]. Another in vitro 
model is the parallel-plate flow chamber, developed originally by Frangos, McIntire, and 
colleagues [23, 49]. In this system, a flow chamber consisting of a polycarbonate plate, a 
rectangular Silastic gasket, and a glass slide (or cover slip) with the attached EC monolayer 
were held together by a vacuum maintained at the periphery of the slide. Although the 
cone-and-plate and the parallel-plate flow chamber systems are the most commonly used 
in vitro shear systems, microfluidic chambers have become more recently used as they 
allow for high throughput experiments. This method was pioneered and commercialized 




1.4.2 In vivo Models of Shear Stress and Atherosclerosis 
 Although in vitro models provide insight into the role of shear stress in endothelial 
biology, in vivo  models allow for the study of shear stress on disease development. These 
models are available in a variety of animals, including pigs, rats, and mice [53]. However, 
due to ease of genetic and physical manipulation, mice are the most popular animal model. 
One of the first models of atherosclerosis was the hypercholesterolemia model developed 
by Paigen et al. [54-57]. It was found that only the C57BL/6J strain could develop 
atherosclerosis if hypercholesterolemia was induced by genetic mutation and high-fat diet. 
The two most widely used mutations are the apolipoprotein E (ApoE) disruption [58-60] 
and the LDL receptor deletion [61]. The most common diets are Paigen’s diet, which 
includes cholate [55], and the Western diet, which does not include cholate and is less 
inflammatory [59, 62]. Other models of atherosclerosis use surgical intervention to the 
arteries to induce atherosclerosis. Specifically, models such as injection of foreign proteins 
[63, 64] in rabbits, drying models in rats [65], and the more established wire [66] and later 
balloon injury models [67, 68] in mice directly injured the artery. However, the constrictive 
perivascular cuff model in mice [69-71] and the ligation models in mice are the most 
popular methods to rapidly induce atherosclerosis by alterations in flow, and thus shear 
stress (in conjunction with hypercholesterolemia). In the perivascular cuff model, the 
constricted region experiences higher shear stress, whereas the proximal section is exposed 
to d-flow and thus develops atherosclerotic plaques. Both complete ligations and 
incomplete ligations are also commonly used. In the complete ligations, the carotid artery 
is ligated, which induces vascular remodeling, neointimal hyperplasia, and atheroma 
formation [17, 71-81].  However, in this model, there is no shear stress. Finally, among the 
incomplete ligations, first studied in pigs [82], we have robustly developed a partial carotid 
ligation model [83]. In this model, 3 of the 4 branches of the left carotid artery is ligated 




















 Mechanosensing and Mechanotransduction in Atherosclerosis 
1.5.1 Mechanosensors 
 On the luminal, junctional, and basal surfaces of ECs, there are numerous 
mechanoreceptors capable of detecting and responding to shear stress stimuli. After 
activation of any one of these mechanoreceptors, a complex network of several intracellular 
pathways is triggered in a process known as mechanotransduction (summarized in Figure 
1.4). These pathways are activated simultaneously and/or cross-talk with each other. These 
pathways lead to regulation of several transcription factors, which bind positive or negative 
shear stress responsive elements (SSREs) in the promoters of mechanosensitive genes, thus 
inducing or suppressing gene expression respectively. Furthermore, a shear stress stimulus 
could trigger a change in conformation of a membrane protein in order to expose previously 
Figure 1.3 Models of flow and shear stress. Cone-and-plate viscometer. 
Adapted from Jo et al. (1991) (A). Parallel plate flow chamber. Adapted from 
Lawrence et al. (1987) (B). Microfluidic flow chamber. Adapted from Schaff 
et al. (2007) (C). Carotid cuff model Adapted from Cheng et al. (2005) (D). 
Partial carotid ligation model. Adapted from Nam et al. (2010). (E). 
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hidden sites. Thus, a new binding site would be available to downstream biochemical 
substrates, which would initiate a cell signaling cascade. Below, we discuss the role of 
major mechanical sensors, including platelet endothelial cell adhesion molecule 1 
(PECAM1), the glycocalyx, caveolins, cytoskeletal structures, integrins, angiotensin type 
1 (AT1) receptor (AT1R), and the nucleus in the regulation of endothelial function. 
 PECAM1 is an important molecule that is present on the endothelial surface and is 
primarily localized to junctions between ECs. PECAM1 becomes phosphorylated at 
tyrosine residues in response to mechanical stimuli. Osawa et al. report that this 
phosphorylation causes association of PECAM1 with SHP-2, a phosphatase that activates 
extracellular signal-regulated kinase (ERK) [84]. ERK activation, which has been 
previously implicated in mechanotransduction, depends on PECAM1 phosphorylation. 
Therefore, it can be speculated that in response to mechanical disturbance of the plasma 
membrane, PECAM1 becomes phosphorylated by an unknown kinase, and subsequently 
recruits SHP-2, thereby activating ERK.  In turn, SHP-2 can dephosphorylate PECAM1, 
however, persistent flow-shear stress could re-initiate the phosphorylation cycle, thus 
maintaining the cellular response [85]. Furthermore, PECAM1 (in complex with vascular 
endothelial growth factor receptor (VEGFR2) and VE-cadherin) activates 
phosphatidylinositol-3-OH kinase (PI3K), which is another mechanosensitive signaling 
kinase. After PI3K is activated, another mechanosensitve kinase which is involved in the 
same signaling pathway as PI3K, Akt, is also activated. Akt activation  leads to cytoskeletal 
arrangement so that ECs exposed to anti-atherogenic LS align in the direction of flow, 
whereas in ECs exposed to pro-atherogenic OS, have Rac1 activation, which in turn leads 
to increased reactive oxygen species (ROS) and NFκB activation. Thus, in OS, the same 






The glycocalyx is also present on the surface of ECs. The glycocalyx  is comprised 
of various macromolecules. Some of these include glycoproteins bearing oligosaccharides 
and terminal sialic acids, proteoglycans, and glycosaminoglycans (GAGs) [88].  The 
glycocalyx constantly senses the shear stress on the endothelium. The glycocalyx also 
interacts with other plasma proteins, enzymes, enzyme inhibitors, growth factors and 
cytokines through structural cationic sites, as well as cationic amino acids, in order to make 
a matrix of biopolyelectrolytes [88-92]. It is frequently observed that the glycocalyx 
undergoes structural and functional modifications when interacting with these molecules 
[93-96]. These properties allow the glycocalyx to function as a selectively permeable 
barrier for macromolecules by filtering molecules based on size and charge. Given its role 
as a selectively permeable barrier, its ability to sense the mechanical forces imposed by 
blood flow, and sequentially transduce these signals into intracellular biochemical 
responses with vasoregulatory properties [97-101], these qualities distinguish the 
glycocalyx as a vital element of a functional endothelium. Likewise, proteoglycans are 
proteins that contain specific sites where sulfated GAGs are covalently attached en 
route from the endoplasmic reticulum to the Golgi apparatus. These constituents provide a 
downstream signaling event upon interaction with the local fluid-shear environment [96, 
102].   
Caveolin-1 is also a membrane-associated element. Specifically, caveolin-1 is a 
protein that associates with cholesterol and sphingolipid-rich regions of the membrane and 
usually forms pits or caveolae. Similarly, glypicans, along with their heparin sulfate chains 
localize to these regions. Transmembrane syndecans are shown to cluster on the outer edge 
of caveolae and along with other molecules, are involved with eNOS signaling. 
Particularly, these molecules have been shown to inactivate eNOS [103-107]. On the other 
side of the plasma membrane, the cytoplasmic tails of the syndecans associate with the 
cytoskeleton and assist in its organization through molecules such as ezrin, tubulin, 
syntenin, syndesmos, dynamin and α-actinin [108-111]. Syndecans also directly associate 
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with proteins involved in signaling, such as protein kinase C-α (PKCα), 
phosphatidylinositol-4,5-biphosphate, and Calcium/Calmodulin-Dependent Serine Protein 
Kinase (CASK), a protein containing both a calcium/calmodulin-dependent and a 
guanylate kinase domain [108, 112-114]. Active participation in signaling stems from the 
phosphorylation of certain intracytoplasmic residues, which act as switches controlling the 
oligomerization state and thus altering the binding properties of syndecans. Ultimately, this 
enables them to orchestrate events on both sides of the membrane [108, 112-114]. Finally, 
it is also worth noting that the secondary structures of all syndecan ectodomains are 
predicted to contain almost exclusively solvent-accessible loops, implying that these 
molecules are flexible (models by PROFsec, and YASPIN) [115, 116]. 
Integrins are also membrane-associated mechanosensors. Integrins are hetero 
dimeric transmembrane proteins comprised of non-covalent interactions between α and β 
subunits that serve as major molecular links between ECs and the ECM. Extracellular 
domains of the α subunits participate in adhesion and ligand recognition, and upon 
activation, the short cytoplasmic domains of β subunits, which lack kinase function, 
physically connect to the cytoskeleton and recruit proteins for signaling [117-120]. The 
specificity of integrin signaling is made possible by α and β-subunits that form the hetero 
dimeric pair. The α-subunit generally confers ECM specificity [120, 121], whereas the β-
subunit interacts with the cytoplasmic environment. Evidence for shear stress activation of 
integrins is provided by both direct assessment of integrin conformational changes in 
response to shear stress and blockade of the shear-induced responses by monoclonal 
antibodies or via the use of the integrin binding Arg-Gly-Asp (RGD) peptide. When cells 
are plated on ECM or treated with integrin-activating monoclonal antibodies, integrin 
activation is manifested by modulations of affinity and avidity [122, 123]. Tzima et al. have 
shown an increased immunostaining of integrins in sheared ECs, indicating a modulation 
of integrin affinity by shear stress [86]. Using multiple monoclonal antibodies to assess 
ligand-bound form of β1 and β3, Jalali et al. have demonstrated that shear stress leads to an 
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increase in integrin avidity in the endothelium [124].  Because integrins lack enzymatic 
activity, activation of signaling factors requires interaction with cellular proteins that have 
kinase activity. In ECs, the cytoplasmic tail of the β-subunit has been shown to directly 
bind to several cytoskeletal proteins that associate with signaling molecules [125]. In other 
cell types, β1 integrin has been shown to be important for coupling mechanical stretch to 
activation of the well-known mechanosensitive signaling pathway members mitogen 
activated protein kinases (MAPKs), as well as focal adhesion kinase (FAK) and Rho 
GTPases [126, 127]. EC motility is a critical function that is regulated by integrins in 
response to hemodynamic forces. The effect of shear stress on EC migration and the 
contribution of the integrins and integrin-dependent signaling pathways have been studied 
in vitro using scratch-wound assays. LS-induced endothelial migration was significantly 
reduced by integrin-receptor blocking with RGD peptides or with neutralizing antibodies 
against integrin subunits αv and β1, whereas antibodies against αvβ3 or α2β1 had no effect. 
Cell-surface levels of the integrin α5β1 were specifically upregulated in migrating ECs at 
the wound edges. Consistent with these previous results, blockade of the integrin-
associated adapter protein Shc by overexpression of dominant negative construct 
inhibited shear stress-stimulated endothelial migration [128, 129].  Collectively, these 
studies imply that integrins are important endothelial mechanosensors and 
mechanotransducers.  
Mechanical forces can also be directly sensed by the actin cortex and, in turn, be 
transmitted as signaling events. However, the mechanisms are poorly understood.  Using 
an integrative approach of combining molecular and mechanical experimental 
perturbations with theoretical multiscale modeling, the process of cortical mechanosensing 
from molecular to cellular scales has been elucidated. Early evidence that the nucleus is 
under tension came from Ingber and coworkers in 1992, who showed that perturbing 
actomyosin forces altered cell and nuclear shape [130]. In a landmark paper in 1997, they 
showed that tugging on integrin receptors in the cell membrane causes nuclear distortion 
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and motion [131]. This established the concept that forces applied externally to the cell are 
propagated to the nuclear surface, which was consistent with mechanical models of the cell 
cytoskeleton that are ‘hardwired’ to the nuclear envelope [132-137]. These external forces 
have now been shown to induce clearly-detectable nuclear deformation [131, 138-145]. 
The F-actin cytoskeleton plays a major role in propagating the mechanical forces from the 
integrin receptors to the nuclear surface, although the molecules which connect the nucleus 
to the cytoskeleton have only recently been identified. In recent years, members of the so-
called LINC complex ( Linker of Nucleoskeleton to the Cytoskeleton) have been 
discovered in the nuclear envelope [146-151]. The LINC complex is comprised of two 
protein families that span the nuclear envelope, and physically connect the cytoskeleton to 
the nucleoskeleton. The SUN (Sad1p, UNC-84) domain proteins span the inner nuclear 
membrane and translumenally bind the KASH (Klarsicht/ANC-1/Syne Homology) 
domain proteins that span the outer nuclear membrane. In this way the KASH and SUN 
domain proteins create a mechanical tether that connects both membranes of the nuclear 
envelope. The KASH domain proteins bind to various cytoskeletal constituents, whereas 
the SUN domain proteins associate with the nuclear lamina [149-151].  Thus, the 
mechanical connections created by the LINC complex can integrate the forces of the 
cytoskeleton and the nucleus. 
In the past decade, numerous studies have indicated that the nucleus itself may act 
as a cellular mechanosensor to directly modulate the expression of mechanosensitive genes 
[152]. The nucleus is tightly integrated into the structural network of the cell through LINC, 
which transmits forces between the nucleus and the cytoskeleton [150]. Lamins, which are 
type V nuclear intermediate filaments, contribute to the nuclear lamina as an extended part 
of the LINC complex. Through this interaction, lamins play a central role in the nuclear 
mechanosensory process. Lamins can be separated into A-type and B-type, with lamins A 
and C as the major A-type isoforms, and lamins B1 and B2 as the major B-type isoforms 
in somatic cells [153]. Lamins A and C provide structural support to the nucleus [140] and 
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play a major role in physically connecting the nucleus to the cytoskeleton, thereby enabling 
forces to be transmitted from the cytoskeleton and extracellular matrix to the nuclear 
interior. Lamins A and C are important contributors to the mechanical stiffness of nuclei, 
whereas lamin B1 contributes to nuclear integrity instead. Cells lacking lamins A and C 
have reduced nuclear stiffness and increased nuclear fragility, which leads to increased cell 
death under mechanical strain. Mutations in lamins A and C result in a variety of severe 
diseases, including dilated cardiomyopathy, which further indicates the critical role of these 
nuclear envelope proteins in maintaining normal cellular function. Recent studies have 
provided some insight into how the nuclear lamina responds to force-induced nuclear 
deformation and couples to biochemical responses in ECs in response to shear stress [138, 
154-157]. However, it remains to be determined whether these changes reflect the role of 
lamins as mechanosensors or if transcriptional regulation of lamins is downstream of other 
mechanosensing pathways. Several other key questions remain to be addressed regarding 
the role of the nuclear envelope proteins in endothelial mechanotransduction. Issues that 
remain to be addressed include whether lamins are mechanosensors or merely serve as 
processing hubs, how the nuclear mechanosensing system is integrated with signaling 
originating from the plasma membrane, and the role of this system during adaptive and 
maladaptive stages of vessel remodeling. 
Finally, G-protein coupled receptor (GPCRs), such as AT1R, can also serve as 
mechanosensors/transducers. One such, AT1R, binds angiotensin II (Ang II) in the 
canonical pathway. However, recently it was found that there are biased ligands of AT1R 
which can be activated by shear stress through an AngII-independent mechanism [158-
162]. It is well established that AT1R, the first mechanosensitive GPCR discovered, 
mediates transformation of mechanical stimuli into biochemical information and gives rise 
to a variety of mechanosensor-induced cellular responses (such as inflammation, cell 
growth, and differentiation etc.) [162, 163].  Recent studies suggest that d-flow induces β-
arrestin-based signaling downstream of AT1R in the absence of ligand or G protein 
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activation [164]. Mechanical stimulus triggered AT1R receptors mediate conformational 
changes in β-arrestin, similar to that induced by a β-arrestin-biased ligand, to selectively 
stimulate receptor signaling in the absence of detectable G protein activation [161, 162, 
165]. Yatabe et al., demonstrated that mechanical stress caused an increase in the 
phosphorylation levels of ERK in rat mesangial cells through the AngII-independent AT1R 















1.5.2 Mechanosensitive Signaling Pathways 
  Shear stress is translated from the cell surface through a variety of mechanosensors 
[166]. Once the shear stress stimulus is applied, various intracellular pathways are triggered. 
Interestingly, many of these pathways converge on common signaling pathways, such as 
the MAPK pathway and the PI3K /Akt pathway [104]. The MAPK pathway in particular 
can be activated through integrins (as previously discussed), among others.  Briefly, 
integrins activated by mechanical stimuli phosphorylate and activate a complex of kinases, 
Figure 1.4 The endothelial cell senses shear stress through mechanosensors. These 
include surface mechanoreceptors (ion channels, receptor tyrosine kinases, G 
protein coupled receptors), cell-cell and cell-matrix adhesion complexes 
(PECAM1/VE-cadherin/VEGFR2 complex and focal adhesion kinases), the 




adaptor proteins, and guanine nucleotide exchange factors, which ultimately lead to the 
activation of Ras. When Ras becomes activated, this leads to the activation of MAPKs. 
ERK1/2, members of the MAPK family, then activate transcription factors (such as c-myc, 
c-jun, and c-fos) and/or eNOS [167]. Furthermore, mechanosensitive membrane proteins 
activate the MAPK pathway through protein kinase C (PKC) [167], whereas NADPH 
oxidase activates the MAPK pathway through ROS [168]. An additional example of such 
is the activation of PECAM1, as discussed previously. Furthermore, the PI3K/Akt pathway 
can converge with the same integrins that the MAPKs interact with and can lead to 
activation of eNOS [169, 170]. 
These shear-responsive pathways often activate the MAPK and PI3K/Akt pathways 
differentially in response to LS vs. OS [171]. In LS, atheroprotective genes become 
upregulated [172-174]. Particularly, eNOS becomes phosphorylated and activated by Akt 
via a PI3K-dependent pathway [175] and leads to an anti-atherogenic phenotype in ECs 
[176]. Krüppel-Like Factor 2 (KLF2) is a mechanosensitive transcription factor which is 
intimately involved in the aforementioned mechanosensitive pathways. Klf2 is critical for 
vascular homeostasis and is a potent anti-atherogenic transcription factor [177]. Klf2 is a 
highly expressed in straight sections of the human aorta that experience LS, but is lower in 
the regions experiencing OS, such as the bifurcation in the iliac and carotid arteries [178]. 
Consequently, KLF2 downregulates a host of pro-inflammatory genes in ECs exposed to 
LS, such as vascular cell adhesion molecule (VCAM-1) and E-selectin, which mediate 
monocyte and T-cell adhesion to the endothelium [179]. Furthermore, KLF2 can inhibit 
the NFκB pathway by recruiting transcriptional coactivators to inhibit interleukin 1 (IL-
1β) and tumor necrosis factor (TNFα)-mediated stimulation. KLF2 also inhibits thrombin-
mediated induction of inflammatory factors, such as monocyte chemoattractant protein 
(MCP-1), IL-6, and IL-8, by inhibiting expression of its principal receptor protease-
activated receptor 1 [180, 181]. Additionally, KLF2 prevents endothelial inflammation and 
thrombosis by preventing nuclear localization of phosphorylated activating transcription 
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factor 2 (ATF2), which mediates the expression of proinflammatory and procoagulant 
genes [182]. To further solidify the role of KLF2 as a potent anti-thrombotic agent, it was 
found that KLF2 overexpression strongly increases TM, which is a cell surface factor that 
inhibits coagulation, and KLF2 inhibits tissue factor and plasminogen activator inhibitor 1 
production. 
However, not only does KLF2 downregulate inflammation and prevent thrombosis, 
KLF2 is also responsible for the shear-induced alignment of ECs. Horrevoets et al first 
linked KLF2 expression to the morphological changes seen in endothelial cells exposed to 
shear. In this study, they found that Jun NH2-terminal kinase and MAPK signaling lead to 
inhibition of the phosphorylation of actin cytoskeleton-associated proteins [183]. KLF2 
promotes vasodilation through the direct transcription of eNOS [184-187] and by inhibiting 
caveolin-1, which regulates eNOS by inducing arginosuccinate synthase, a limiting 
enzyme in eNOS substrate bioavailability [184-187]. In the long term, sustained expression 
of KLF2 inhibits expression of endothelin-1, adrenomedullin, and angiotensin converting 
enzyme, all ofwhich increase vascular contractile tone [188]. 
Furthermore, KLF2 inhibits angiogenesis and EC proliferation via inhibition of 
VEGF-A[189] and VEGFR2 expression by competing with its transcription factor Sp1 at 
the promoter. In addition to these mechanisms, KLF2 can inhibit angiogenesis through 
semaphorins, have been shown to inhibit EC migration. Klf2 can be upregulated by LS 
indirectly through the LS effect on the MAPK pathway (namely MEK5 and ERK5)  [190]. 
KLF2 is regulated through a variety of mechanosensitive pathways. These include LS 
induction of MAPK pathway, which causes histone deacetylase 5 (HDAC5) dissociation 
from MEF2, thus allowing MEF2 transcription of KLF2 mRNA [191], PI3K inhibition by 
prolonged flow via Tie2, AMP-activated protein kinase activation by LS activating ERK5-
MEF2. KLF2 mRNA is also stabilized via PI3K pathway [192]. Furthermore, OS causes 
prolonged suppression of KLF2 by the src signaling pathway [193]. Additionally, the OS 
sensitive gene regulator HuR plays a role in KLF2 regulation. Specifically, downregulation 
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of HuR leads to KLF2 mRNA stabilization [194]. Pro-inflammatory cytokines such as 
TNFα and IL1β repress KLF2 expression via HDAC4 and p65 (component of NFκB) 
cooperatively inhibiting MEF2 [195]. Finally, oxidative stress can also decrease KLF2. 
SUMOylation of ERK5 by hydrogen peroxide and advanced glycation end products 
inhibits KLF2 expression by decreasing MEF2 [196] and the Shc oxidative stress protein 
p66shc [197] reduces MEF2A expression as well. 
Another transcription factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a 
target of KLF2, is also mechanosensitive, and in conjunction with KLF2, controls 70% of 
the genes induced by LS [187]. Nrf2 becomes translocated to the nucleus in cultured 
endothelial cells exposed to LS [198]. Nrf2 which exerts its anti-atherogenic effects by 
modulating ROS and reactive nitrogen species (RNS) [174]. Shear stress plays a critical 
role in the production of ROS and RNS in ECs. Shear stress activates NADPH oxidase, 
resulting in production of superoxide (O2-)  [197, 199-201]. Xanthine oxidoreductase also 
contributes to superoxide production in response to OS [202].  In addition, NO is generated 
(via eNOS) [106, 203-206] Although NO plays an important role in vasodilation [207-209] 
and inflammation [161, 210]. NO may react with superoxide, thereby forming peroxynitrite 
(ONOO-), which is highly reactive. Peroxynitrite can modify proteins and lipids and induce 
oxidative damage [211, 212].  Although both OS and LS induce superoxide and NO, the 
balance between the species determines the overall effect. In the case of LS, NO production 
is significantly higher than that of OS [213, 214]). Whereas in OS, superoxide production 
is much higher [202, 215-217] but eNOS is upregulated to a much lesser extent [218-220], 
which in turn leads to the reaction of NO with superoxide to form peroxynitrite, resulting 
in less bioavailable NO. In contrast, LS upregulates the expression of eNOS strongly, as 
well as dismutases that can convert superoxide into other species, thus preventing 
peroxynitrite formation. These include copper/zinc superoxide dismutase (CuZnSOD) and 
manganese (MnSOD) [221, 222]. Nrf2 is essential for upregulating cytoprotective genes 
under LS [174, 223, 224]. Nrf2 binds to the antioxidant response element (ARE) in its 
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target genes, which include phase II detoxification enzymes and antioxidant proteins, such 
as glutathione-S-transferase, HO-1, peroxiredoxin 1, NQO1, GCLM, and GCLC [212, 225, 
226]. These enzymes are crucial for protecting cells from electrophile toxicity and 
oxidative stress.  
Nrf2 is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1), 
which facilitates the degradation of Nrf2 through the proteasome [193]. In response to 
oxidative stimuli, Nrf2 becomes activated by its dissociation from Keap1, which undergoes 
electrophilic attack that causes it to undergo the conformational change to dissociate from 
Nrf2 [30, 196, 227, 228]. In turn, Nrf2 upregulates its anti-oxidant target proteins [229, 
230]. The upregulation of Nrf2 in LS is ROS dependent, as Nrf2 activation in LS was 
blocked by ROS scavengers [224, 231-235] and NADPH oxidase inhibitors. The 
subsequent ROS/RNS modifies Keap1 under LS conditions so that Nrf2 is no longer 
suppressed. 
As opposed to LS, in OS , ECs express pro-inflammatory cytokines such as MCP-
1 [169] and inflammatory cell adhesion molecules such as VCAM1 and ICAM1  [236]. 
The chemokine MCP-1, contains a phorbol ester (TPA)-responsive element (TRE) in its 
promoter region, which was also found to be shear-sensitive and regulated through MAPKs 
[169]. Similarly, VCAM1 and ICAM1 also contain these shear-responsive elements in their 
promoters [236]. Furthermore, ECs express other pro-inflammatory, shear-sensitive 
proteins such as NADPH oxidase [174], and bone morphogenetic protein (BMP4) [237]. 
Two of the main transcription factors that are responsible for the upregulation of many of 
these pro-inflammatory genes such as ICAM1, VCAM1, and E-selectin are the activator 
protein complex (AP-1) and nuclear factor (NFκB) complex [116, 183, 238-242].  
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NFκB is comprised of p65 (RelA) and p50, and its activity is regulated by its 
intracellular location. Under basal conditions, NFκB is located in the cytosol bound to 
IκBα. Under stimulation, IκBα becomes phosphorylated by IκB kinase, and thus NFκB 
becomes free to pass into the nucleus and bind to target genes for transcription. Whereas 
AP-1 is a heterodimer composed of different proteins from either the c-Fos, c-Jun, ATF, 
or JDP families depending on the target gene. ROS produced by NADPH oxidase or other 
oxidases can directly activate NFκB and AP-1 [243, 244] in MAPK, ERK, and c-Jun N-
terminal kinase (JNK) dependent pathways [172, 245-249]. Ultimately, these findings 
have demonstrated that LS upregulates “atheroprotective” genes and downregulates 






Figure 1.5 Shear stress leads to the activation of multiple intracellular pathways. 
(A) LS activates pathways that result in alignment in the direction of flow, 
increased NO production, and suppression of inflammatory cell adhesion 
molecules. (B) On the other hand, OS induces high expression of cell adhesion 
molecules, production of inflammatory cytokines, high oxidative stress, and a 
leaky cell barrier Adapted from Noguchi & Jo (2011). 
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 MicroRNAs and Atherosclerosis 
1.6.1 Biogenesis of miRNAs 
 microRNAs (miRNAs) are a large class of evolutionarily conserved, noncoding 
RNAs, typically 18 to 22 nucleotides in length. miRNAs primarily function as post-
transcriptional regulators by interacting with the 3’ untranslated region (3’ UTR) of 
specific target mRNAs in a sequence-specific manner[250, 251].  . It is thought that a single 
miRNA can target hundreds of mRNAs. miRNAs are transcribed by RNA polymerase II 
and can be derived from individual miRNA genes, from introns of protein coding genes, 
or from polycistronic transcripts that often encode multiple, closely related miRNAs. Pri-
miRNAs are processed in the nucleus by the RNase Drosha into 70–100 nucleotides, 
hairpin-shaped precursors, called pre-miRNAs. Following transport to the cytoplasm, the 
pre-miRNA is further processed by the RNA endonuclease Dicer to produce a double-
stranded miRNA. The fully processed miRNA duplex is then incorporated into a 
multicomponent protein complex known as RNA induced silencing complex (RISC), of 
which argonaute (Ago2) is a member of. During this process, one strand of the miRNA 
duplex is selected as a mature miRNA while the other strand, known as miRNA*, is rapidly 
removed and degraded [252-255]. As part of the RISC, miRNAs negatively regulate 
gene expression through translational repression or mRNA cleavage, depending on 

























1.6.2 Mechanosensitive Endothelial-Derived miRNAs in Atherosclerosis 
 It has been previously demonstrated that LS and OS differentially regulate the 
expression of miRNAs in endothelial cells. The majority of flow sensitive miRNAs have 
been identified and characterized in vitro . However, a select few were subsequently 
validated in vivo . Therefore, only a limited number of direct links to atherosclerosis have 
been established. Current literature divides these shear-sensitive miRNAs into three classes 
according to their reported effects [256] (summarized in Figure 1.7): (A) anti atherogenic 
(B) dual role and (C) pro atherogenic. Anti atherogenic miRNAs include miR-10a, 19a, 
23b, 101, 143 and 145, all of which are either upregulated by LS or are downregulated by 
d-flow/OS. Dual role miRNAs include miR 21, 155, and 126. Dual-role miRNAs have 
been implicated in both pro and anti-atherogenic events. Pro atherogenic miRNAs include 
miR-17~92, 92a, 663, 712, and 205, all of which are either upregulated by d-flow/OS or 
are downregulated by LS.  






 miR-10a was one of the first to be identified as mechanosensitive. Its expression in 
the endothelium is decreased by d-flow in the athero-prone, lesser curvature region (LC) 
of the porcine aortic arch as compared to that of the athero-protected, thoracic aorta 
(TA)[257].  Mechanistically, miR-10a prevents inflammation by targeting MAP3K7 and 
TRC, both of which promote IB degradation (NFB inhibitor) and p65(NFB subunit) 
translocation[257]. Later studies using HUVECs found that following 12 hours of LS (12 
dyn/cm2), 35 miRs were upregulated and 26 miRs were downregulated as compared to 
static controls.[258]. Among these, LS increased expression of miR-19a, which targets 
cyclin D1, thus inhibiting proliferation[258]. Subsequent studies identified 8 upregulated 
and 13 downregulated miRNAs in response to 24 hours of pulsatile LS (12±4 dyn/cm2) as 
compared to the static controls[259]. One of the upregulated miRNAs was miR-23b, which 
suppressed endothelial proliferation by reducing E2F1 expression and Rb 
phosphorylation[259].  Other anti-atherogenic miRNAs include miR-101, which is 
upregulated in response to LS and was reported to target the mTOR gene (inducing cell 
cycle arrest[260]) and miR-143/145, which increase by LS in an AMPKα2-dependent 
manner[261] and in a KLF2-dependent manner[262].  
Dual Role miRNAs 
 Although miR-21 was upregulated by LS in HUVECs and was shown to prevent 
apoptosis (by targeting PTEN[263]), another study showed that OS upregulated miR-21 in 
a time-dependent manner. Furthermore, it was shown to inhibit PPARα, thus leading to the 
enhanced expression of VCAM1[264]. Interestingly, miR-21 was increased in arterial 
endothelium exposed to d-flow in the mouse PCL model[83, 265].  Whether miR-21 plays 
a pro or anti-atherogenic role still remains to be determined.  Similarly, the effect of flow 
on the miR-126 and its role in atherosclerosis is also not well understood.  Both 
miR-126-5p and 3p) are highly expressed in ECs and have been shown to regulate vascular 
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integrity, angiogenesis[266], and inflammation[267].  The secretion of miR-126-3p into 
conditioned media was decreased by LS in HUVECs[268].  Furthermore,  knockout of 
miR-126 inhibited neointimal formation in a complete carotid ligation model, while local 
reintroduction of miR-126 in the knockout mice enhanced neointimal formation. However, 
a recent study showed that d-flow decreased expression of both miR-126-5p and 126-3p, 
treatment with the miR-126-5p mimic reduced atherosclerotic lesion formation, and 
miR-126-5p directly targets the Notch1 inhibitor, Dlk1, which promotes EC 
proliferation[269].  Another interesting report from the same group showed that 
miR-126-3p present in apoptotic bodies had an atheroprotective effect in a murine carotid 
cuff model of atherosclerosis[269].  Finally, the role of miR-155 in atherosclerosis is also 
unclear. Its expression is increased by LS in HUVECs and it is abundantly expressed in the 
intima of the athero-resistant TA[270]. However, other studies showed that miR-155 
mediates pro-atherogenic responses[271, 272]. Specifically, miR-155 was shown to 
directly target eNOS mRNA in HUVECs and impair endothelium-dependent vascular 
relaxation in human arteries[273]. Furthermore, leukocyte-specific miR-155 deficiency 
reduced plaque size and lesional macrophage count in the PCL model of 
atherosclerosis[271].   Another study showed that genetic knockdown of miR-155 
ameliorated atherogenesis in ApoE−/− mice by reducing inflammatory responses of 
macrophages and increasing macrophage cholesterol efflux[272]. Ultimately, the role of 
miR-155 in atherosclerosis, as well as all miRNAs, may depend on the specific cell 
type and time-scale. 
Pro-atherogenic miRNAs 
 The miR-17∼92a cluster comprises several miRs, including miR-17, 18a, 19a 19b, 
20a and 92a. Of these, miR-17, miR-19b, miR-20a, miR-92a are mechanosensitive. 
Specifically, they were downregulated by 24 hours of pulsatile LS[191]. Subsequent 
studies showed that miR-92a was downregulated by LS and was upregulated by OS[274]. 
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These in vitro findings are consistent with in vivo studies showing that ECs in the porcine 
aortic arch have increased miR-92a levels as compared to those of the thoracic aorta[274]. 
Further studies demonstrated that miR-92a induced endothelial inflammation by targeting 
KLF2 and KLF4 [275].   
From our mouse model of d-flow-induced atherosclerosis, we identified miR-712 
and miR-205 and established their function in two different animal models of 
atherosclerosis [36]. We found that d-flow induced expression of miR-712, and that it 
contributed to endothelial dysfunction, and thus atherosclerosis. Additionally, treatment 
with antimiR-712 prevented plaque development.  The pro-inflammatory and 
pro-atherogenic effects of miR-712 were mediated by its target, tissue inhibitor of 
metalloproteinase-3 (TIMP3). Loss of TIMP3 by miR-712 resulted in activation of MMPs 
and a disintegrin and metalloproteinases (ADAMs), ultimately leading to endothelial 
inflammation, hyper-permeability, and atherosclerosis [36]. Interestingly, miR-712 is 
murine-specific, but miR-205 is a homolog which is conserved in humans and other 
vertebrates[36], also targets TIMP3, and is also mechanosensitive [36]. In addition to miR-
712 and miR-205, our lab also identified a primate-specific miRNA, miR-663, as the most 
highly upregulated by OS in HUVECs using a miRNA array derived from 24 hours of OS 
vs. LS[276]. Furthermore, we found that inhibition of miR-663 in HUVECs correlate with 
decreased adhesion of monocytes even in OS conditions. Finally, we also found that 
increasing miR-663 in LS increases monocyte adhesion, thus implicating miR-663 in 
endothelial inflammation[276]. Consistent with this report, miR-663 was upregulated in 
HUVECs exposed to pro-atherogenic oxidized phospholipids, and was found to play a 
permissive role in the induction of VEGF and activation of ATF4 branch of unfolded 
protein response in ECs [277, 278]. Although these initial studies indicate miR-663 may 
be pro-inflammatory in humans, the study of miR-663 and its human targets is 








1.6.3 miRNA Animal Studies in Atherosclerosis 
 Many miRNAs have previously been identified as playing a role in 
atherosclerosis by their actions in the endothelium, smooth muscle cells, macrophages, or 
in cholesterol transport [256]. Some of the previously discussed mechano-miRs have been 
investigated as potential therapeutic targets for atherosclerosis through the use of antimiRs 
or knockout mice, including miR-712, 92a, 155, and 126, however, some non-
mechanosensitive miRNAs have also been shown to be potential therapeutics in 
atherosclerosis. These include miR-1, 30c, 144, 146a, 181b, 195, 467b, 342, and 33. These 
studies were conducted using either antimiRs, mimics, adenoviral delivery, or knockout 
mice. 




Anti-Atherogenic miRNAs Studies: Mimics and Viral Delivery 
 miR-1, 146a, 181b, and 195 have all been shown to reduce inflammation by 
their actions in the endothelium and in SMCs. Specifically, inhibition of miR-1 using 
antago-miR enhanced the endothelial hyper-permeability induced by 
hypercholesterolemia, whereas miR-1 mimic prevented endothelial barrier 
dysfunction[279]. Additionally, miR-146a mimics prevented endothelial activation by 
targeting HuR, thus repressing the NFκB and MAP kinase pathways, whereas deletion of 
miR-146a in mice aggravated endothelial inflammation [280]. Similarly, systemic delivery 
of miR-181b mimics reduced atherosclerosis through inhibition its target gene, 
importin-α3, which mediates NFκB nuclear translocation [281, 282].  Also, adenoviral 
delivery of miR-195 reduced neointimal formation in a balloon-injury carotid artery model 
by inhibiting VSMC proliferation, migration, and IL-1β, IL-6, and IL-8 synthesis [283]. 
 Alternatively, miR-30c, 144, and 467b play an important role in the 
regulation of plasma cholesterol level, which is a critical risk factor of atherosclerosis.  
Overexpression of miR-30c via lentivirus in the liver reduced the hyperlipidemia seen in 
Western diet-fed mice by decreasing lipid synthesis and the secretion of triglyceride-rich 
ApoB-containing lipoproteins, which in turn prevented atherosclerosis in 
ApoE-/- mice[284]. Also, miR-467b mimic delivery reduced plasma cholesterol and 
atherosclerosis. Alternatively, miR-467b inhibition by using antago-miR-467 enhanced the 
progression of atherosclerosis by increasing lipid accumulation and inflammatory cytokine 
secretion [285]. Finally, miR-144  mimics decreased hepatic ABCA1 and HDL cholesterol, 
but its contribution to the development of atherosclerosis is unknown [286].  
Pro-Atherogenic miRNAs Studies: AntimiRs 
 miR-342 and miR-33 are both pro-atherogenic miRs. Specifically, miR-
342-5p is a macrophage-derived miRNA that increases atherosclerosis and inflammatory 
stimulation of macrophages through inhibition of Akt1 [287]. Suppression of Akt1 by 
miR-342-5p indirectly induces Nos2 and IL-6 in macrophages through miR-155.  
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Therefore, systemic miR-342-5p inhibition reduced atherosclerotic plaque development in 
the aorta of ApoE-/- mice.   
 Multiple studies show that silencing of miR-33 prevents inflammation and 
atherosclerosis [288-290]. AntimiR-33 treatment or genetic knockout of miR-33 in mice 
promotes reverse cholesterol transport and inhibition of atherosclerosis through regulation 
of ABCA1[288, 289, 291]. Also, antimiR-33 increased hepatic expression of ABCA1 and 
induces a sustained increase in plasma HDL in a non-human primate model[292]. 
However, a recent report showed that long-term silencing of miR-33 with antimiR-33 
failed to demonstrate the anti-atherogenic effects in LDL receptor knockout mice [291].  
The inconsistent responses reported in these studies may reflect a different target genes and 
roles of miR-33 in various cells and tissue types. While miR-33 may ABCA1 in 
hepatocytes, it may regulate other, unknown target genes in other cell types. Thus, these 
observations raise an important concern regarding the off-target effects of 
systemically delivered miRNA mimics, antimiRs, or antago-miRs in animal studies 
and clinical use.  
1.6.4 miRNAs in the Clinic  
Given the increasing number of in vivo studies using miRNAs both in the 
atherosclerosis field and beyond, some miRNA studies have moved into clinical trials. 
These include antimiR-122, both LNA modified and galactose conjugated, antimiR-
103/107 (galactose modified), antimiR-155 (LNA), miR-29 mimic, miR-16 mimic, and 
miR-34 mimic [293].   
Pro-atherogenic miRNAs Therapies: AntimiRs 
The first of these was the LNA-modified antimiR-122, which is a 15-nucleotide 
antisense RNA oligo complementary to the 5ʹ end of miR-122. The antimiR is known as 
Miravirasen and is intended for the treatment of Hepatitis C Virus (HCV). Preclinical 
studies in rodents and in non-human primates indicate the antimiR passively accumulates 
in the liver and decreases cholesterol accumulation and reduced titers of HCV [294-296].  
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A Phase I clinical trial was initiated in 2009 and no adverse reactions were reported, thus 
prompting the launch of a Phase II trial. In the first Phase II Trial, 9 patients were enrolled 
in 4 groups, each of which received a dose of 3, 5, or 7 mg/kg Miravirsen or placebo once 
a week for 5 weeks. Patients experienced a significant dose-dependent reduction in HCV 
load and serum cholesterol levels. [297]. However, a more recent follow-up study showed 
mutations near the end of 5ʹ UTR of HCV viral RNA in both in vitro samples and in clinical 
samples [298].  
Alternatively, RG‑101 (Regulus Therapeutics), is a N-acetyl-D-galactosamine 
(GalNAc)-conjugated antimiR against miR‑122. It has also undergone Phase I trials in 
HCV-infected patients at a single dose of 2–4 mg per kg. Furthermore, Phase II trials have 
combined RG‑101 with direct-acting antivirals such as Harvoni (a combination of 
ledipasvir and sofosbuvir), but the (see Regulus Therapeutics, press release dated 7 June 
2016). However, the trial was put on hold by the US FDA after a second case of jaundice 
was reported (see Regulus Therapeutics, press release dated 1st Nov 2016). 
 Furthermore, RG‑125, a GalNAc-conjugated antimiR against miR‑103/107, 
recently entered clinical trials for the treatment of non-alcoholic fatty liver disease. 
Furthermore, mir‑103/107 expression is increased in the liver of obese mice and promotes 
diabetes progression by targeting caveolin 1, a protein involved in insulin signaling. 
Therefore, it is also being investigated at the pre-clinical stage in mice [299]. Finally, LNA-
based antimiR‑155 (MRG‑106; miRagen Therapeutics) has recently entered clinical trials 
to treat patients with cutaneous T cell lymphoma. 
Anti-Atherogenic miRNAs Therapies: Mimics 
 In addition to antimiRs, miRNA mimics have also entered clinical trials. 
One of the most advanced is MRX34, a miR‑34 mimic by Mirna Therapeutics. It is 
encapsulated in a lipid carrier called NOV40, Preclinical studies of mice treated with 
MRX34 nanoparticles showed an accumulation of miR‑34 in tumors with significant tumor 
regression [300-303]. MRX34 entered a multicentre phase I trial in 2013 in patients with 
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primary liver cancer, small cell lung cancer, lymphoma, melanoma, multiple 
myeloma or renal cell carcinoma. The trial included either a dosage a two times per week 
or five times per day schedule, via intravenous infusion. At the end of the trial, analysis of 
white blood cell samples showed significant reduction in the miR‑34 target mRNAs 
FOXP1 and BCL2. However, the trial was terminated due to patient deaths (see Mirna 
Therapeutics Halts Phase 1 Clinical Study of MRX34) [304]. 
 Finally, miR-16 mimics have been entered Phase I Trials in a collaboration 
between EnGeneIC and the Asbestos Diseases Research Institute of Australia, for patients 
with malignant pleural mesothelioma. miR‑16 was delivered in an EDV nanocell with 
EGFR antibody surface conjugation, which facilitates targeting to the tumor site. 
Preliminary data reported manageable safety in response to infusion of 5 billion nanocells 
loaded with 
1.5 μg miR‑15/16 mimics as a first dose level in the first five patients that had been 
enrolled [305]. Finally, two Phase I clinical trials of the miR‑29 miRNA mimic MRG‑201 
(miRagen Therapeutics) have been initiated in patients with scleroderma.  
Although a considerable number of studies involving miRNA therapeutics 
have been conducted over the years, only a small number of miRNA therapeutics have 
moved into clinical development. One of the biggest challenges in developing miRNA-
based therapeutics is maximize stability and minimize off-target effects. 
1.6.5 TSB Studies 
 Given the wealth of targets for each individual miRNA, one of the pitfalls 
of targeting miRNAs is limiting targets to a single target. To address this, recent technology 
has been developed by Exiqon to specifically block the interaction between a miRNA and 
the 3’UTR of its target. Target site blockers (TSBs) are already in use now. TSB usage has 
been reported for miR-29b, 181a, 26, 155, and 103.  
 miR-29b is dysregulated in breast cancer. It was found that miR-29b was 
downregulated in human breast cancer tissue and that overexpression decreased cancer cell 
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growth, self-renewal, migration, invasiveness and paclitaxel resistance via SPIN1. 
Furthermore, they found that silencing SPIN1 mirrored the effects triggered by miR-29b 
overexpression, whereas SPIN1 rescue by TSBs reversed the molecular effects produced 
by the mimic, thus indicating the efficacy of TSBs [306]. 
 miR-155 TSBs have been reported both in vitro [307] and a separate study 
in vivo  [308]. In the in vitro study, miR-155 was found to induce cell migration in colon 
cancer cells by targeting RhoA in colon cancer cells. miR-155 binding to RhoA mRNA 
was verified using TSBs and functionally validated by RNA immunoprecipitation assays 
[307]. Whereas another study used TSBs for miR-155 against the Cebpb 3′ UTR. 
Furthermore, the same study used TSBs against 200b/200c/429-binding sites in the Zeb1 
3′ UTR. These TSBs were used to modulate gonadotropin releasing hormone (GnRH) in a 
study of hypogonadotropic hypogonadism and infertility in mice [308]. Another study 
which utilized TSBs in vivo studied the effect of blocking the interaction between Smad1 
and miR-26. They found that the TSBs inhibited key patterning functions in Xenopus laevis 
embryos [309].  
 Very few studies have utilized TSBs as therapeutics. One such study investigated 
miR-181a inhibition on stroke in mice [310]. In this studies, TSBs designed to block the 
interaction between 181a and estrogen receptor-α (ERα) were used in a mouse model of 
stroke. A miR-181a/ERα TSB, with/without miR-181a mimic, was used to confirm 
targeting of ERα by miR-181a in astrocytes. Individually, miR-181a inhibition decreased 
infarct volume and improved neurologic score in female mice. Treatment with ERα TSB 
was strongly protective in both sexes. Finally, a recent report has emerged directly 
investigating TSB treatment in atherosclerosis [311]. In this study, TSBs blocking the 
KLF4-miR-103 interaction blocked atherosclerosis in a HFD-induced model of 




 MicroRNA miR-744 in Disease Development and Implications for 
Atherosclerosis 
 Fortunately, miR-744 is a broadly conserve miRNA that shares 7 out of the 8 
nucleotides in the seed region with miR-663[312]. Unlike  miR-663, miR-744 is derived 
from the intronic region of the MAP2K4 gene[313] and has not previously been described 
in the endothelium. Rather, miR-744 was first identified in human head and neck cancer 
tumor samples[314]. Following this original publication, other investigators have found 
that miR-744 is highly expressed in humans with gastric  cancer[315], pancreatic 
cancer[316], and nasopharyngeal cancer[317], and interestingly, in patients with heart 
failure[318]. Furthermore, miR-744 has been reported as being highly expressed in mouse 
serum[319] and in murine models of disease such as diabetes[320, 321] and ischemic 
skeletal injury[322].  
A variety of direct targets have been reported for miR-744. One of the first reports 
of miR-744, by Martin et al, demonstrated that TGFβ1 is a direct target of both miR-663 
and miR-744 by qPCR, western blot, and luciferase assay in human proximal tubular 
epithelial cells[323]. Later, it was reported that eukaryotic elongation factor (eEF1A2) is a 
direct target of both miRNAs in a human breast cancer cell line MCF7 by qPCR, western 
blot, and luciferase assay[324]. Furthermore, secreted frizzled-related protein 1 (SFRP1), 
glycogen synthase kinase 3β (GSK3β), and transducin-like enhancer of split 3 (TLE3), 
which are important negative modulators of the Wnt/β-catenin signaling pathway, were 
identified as direct targets of miR-744 in a human pancreatic cell line by luciferase 
assay[325]. Recently, protein-tyrosine phosphatase 1B (PTP1B), which is a ubiquitously 
expressed phosphatase, was also identified as a direct target of miR-744 by luciferase assay 
in human renal mesangial cells[326]. Given that miR-744 is upregulated in a variety of 
disease states in both humans and mice, miR-744 may be important in atherosclerosis 




 LIM Zinc Finger Domain Containing 2 (LIMS2) was first identified in 2002 by 
Zhang et al. [327]. They found that LIMS2, also known as PINCH2, forms a complex with 
the focal adhesion protein integrin-linked kinase (ILK) through interactions with the first 
LIM domain. PINCH2 localizes to both cell-ECM contact sites and the nucleus by 
interacting with ILK. Interestingly, two other LIM domain family members shuttle between 
the cytoplasm and nucleus. These are zyxin [328, 329] and HIC-5 [330, 331], which play 
a role in gene transcription in the nucleus. Furthermore, PINCH2 is co-expressed with the 
previously discovered isoform PINCH-1 in multiple cell types [332]. Finally, PINCH2-
ILK and PINCH1-ILK interactions may be mutually exclusive in that overexpression of 
PINCH2 significantly inhibited the PINCH1-ILK complex in this study and a follow-up 
study [327, 333].  
 Later it was discovered that the structural basis for PINCH1 vs PINCH2 biased 
binding is that the LIM1 domains of PINCH1 and PINCH2 directly compete for the same 
binding site on the ankyrin repeat domain (ARD) of ILK. It was determined that the 1.9 Å 
crystal structure of the PINCH2 LIM1 domain complexed with the ARD of ILK, and 
disruption of this interface by point mutagenesis reduces binding in vitro and alters 
localization of PINCH2 in cells [334]. The direct competition of PINCH-1 and PINCH-2 
for ILK binding may provide differential integrin signaling [335]. However, it has also 
been reported that PINCH2 can partially compensate for the loss of PINCH1 in preventing 
ILK degradation by the proteasome but not cell survival [336].  
 Pathologically, PINCH2 global knockout mice do not exhibit any diseased 
phenotype and appear to be viable and normal, albeit with significantly increased PINCH1 
expression. Double knockout fibroblasts from the mice had increased ILK degradation, 
which was rescued by overexpression of alone [337]. Similarly, PINCH2 global knockout 
mice with hepatocyte-specific PINCH1 knockout were born normally but experienced 
abnormalities of the liver, where both PINCH1 and 2 were absent. Specifically, the mice 
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had enlarged, stiff livers due to reduced expression of Rsu1, which suppresses Ras 
signaling and cell migration [338]. Finally, it appears that inactivation of PINCH1 and 
PINCH2 independently leads to instability of ILK, loss of stretch-responsive VEGF 
expression, and progressive heart failure in zebrafish [339]. In agreement with these 
findings, Liang et al reported that deletion of cardiac-specific PINCH1 knockout or global 
PINCH2 knockout mice exhibit no basal cardiac phenotype, but mice that are doubly 
homozygous null for PINCH1 and PINCH2 in the myocardium developed dilated 
cardiomyopathy and died of heart failure within a few weeks and fibrosis and reduced 
expression/mislocalization of multiple cell adhesion proteins [340] 
 Despite the intertwined roles of PINCH1 and 2, PINCH2/LIMS2 alone has been 
found to be silenced by hypermethylation in gastric cancer cells, which ultimately 
promoted increased cell migration in vitro [341]. In human patients, it was discovered by 
sequencing that compound heterozygous missense mutations in LIMS2 lead a loss of 
LIMS2 in Limb Girdle Muscular Dystrophy and cardiomyopathy [342]. Given the 
evidence that both PINCH1 and 2 play a role in cardiac pathology, LIMS2 alone is 
lost in cardiomyopathy, and LIMS2 alone can rescue ILK (an important 
mechanosensitive signaling component) from degradation, LIMS2 may play a key 
role in endothelial mechanosensing. 
 ILK Signaling, Focal Adhesions, and Atherosclerosis 
ILK is a widely expressed, mechanosensitive, serine/threonine kinase that binds to 
the C terminus of β1-integrin [343]. Many proteins associated with mechanosensing have 
been shown to bind to different domains of ILK including α-actinin via β-parvin/affixin 
and the aforementioned PINCH and thymosin β4 [335, 344].  It has also been shown to 
phosphorylate myosin light chain, GSK-3β (glycogen synthase kinase-3β), and AKT/PKB 
[345]. ILK has previously been implicated to play a role in cardiac physiology. In fact, it 
was identified as an essential regulator of cardiac growth, contractility, and repair [346] . 
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ILK gene knockouts in mice, flies, and worms result in early embryonic lethality because 
of cell adhesion defects and cytoskeletal disorganization. Although widely distributed in 
mammalian tissues, ILK expression is highest in the heart, and cardiac-specific ablation of 
ILK causes cardiomyopathy and sudden death in mice [347].  
 Bendig et al. a mutation in the ILK gene that causes progressive loss of contractility 
in zebrafish hearts. This mutation disrupted the interaction with β-parvin/affixin, 
suggesting that its presence is essential for normal cardiac function and potentially cardiac 
stress sensing [348]. Likewise, in another zebrafish study, a nonsense mutation (Y319X) 
led to a dysmorphic ventricle with reduced cardiac function combined with severe 
endothelial defects, similar to alterations observed in mice lacking the integrin-binding 
extracellular matrix protein laminin α4 [349].  
  ILK has recently been directly implicated in atherosclerosis. It was discovered that 
ILK is strongly expressed in the endothelial cell layer of non-atherosclerotic vessels but 
was absent from the endothelium of atherosclerotic arteries. Also, vasodilation was 
impaired in ILK knockout mice. Furthermore, these mice exhibited eNOS uncoupling, 
reflected in reduced tetrahydrobiopterin (BH4) levels, increased BH2 levels, decreased 
dihydrofolate reductase expression, and increased eNOS-dependent generation of 
superoxide accompanied by extensive vascular protein nitration. ILK re-expression 
prevented eNOS uncoupling in knockout cells, whereas superoxide formation was 
unaffected by ILK depletion in eNOS-KO cells, indicating eNOS as a primary source of 
superoxide anion. eNOS and ILK coimmunoprecipitated in aortic lysates from control 
animals, and eNOS-ILK–shock protein 90 interaction was detected in human normal 
mammary arteries but was absent from human atherosclerotic carotid arteries. eNOS- ILK 
interaction in endothelial cells was prevented by geldanamycin, suggesting heat shock 
protein 90 as a binding partner. Our results identify ILK as a regulatory partner of eNOS 
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in vivo that prevents eNOS uncoupling, and suggest ILK as a therapeutic target for 
prevention of endothelial dysfunction related to shear stress–induced atherosclerosis [350] 
Furthermore, in a follow-up study, it was discovered that increased levels of 
inducible nitric oxide inversely correlated with decreased ILK levels in human 
atherosclerosis and in a mouse model of vascular remodeling (carotid artery ligation) 
comparing Furthermore, it was discovered that NO decreased ILK protein stability by 
promoting the dissociation of the complex ILK/heat shock protein 90/endothelial NO 
synthase, leading to endothelial NO synthase uncoupling. NO also destabilized ILK 
signaling platform and lead to decreased levels of paxillin and α-parvin. ILK 
phosphorylation of its downstream target GSK3-β was decreased by NO. Mechanistically, 
NO increased ILK ubiquitination mediated by the E3 ubiquitin ligase CHIP, but ILK 
ubiquitination was not followed by proteasome degradation. Alternatively, NO drove ILK 
to degradation through the lysosome [351]. Given these results, preventing ILK 
degradation in atherosclerosis may be a key therapeutic strategy. 
A substantial portion of this chapter was published in: 
Simmons, R., Kumar, S., Thabet, S., Sur, S., Jo, H. Omics-based approaches to understand 
mechanosensitive endothelial biology and atherosclerosis. WIREs Syst Biol Med. 8: 378-
401. DOI:10.1002/wsbm.1344 (2016) 
Simmons, R., Kumar S, Jo H. The role of endothelial mechanosensitive genes in 
atherosclerosis and omics approaches. Arch Biochem Biophys. 591:111-31. PMID: 
26686737 (2016) 
Kumar, S. Kim, C.W., Simmons, R., Jo, H. Role of Flow-Sensitive microRNAs in 






CHAPTER 2 SPECIFIC AIMS AND HYPOTHESES 
 Significance and Impact 
  Cardiovascular disease (CVD) is the number one cause of death in the US. 
Atherosclerosis, an inflammatory disease characterized by plaque accumulation on the 
arterial walls, is the major cause of CVD. Atherosclerotic plaque rupture (thrombosis 
and embolism) blocks blood flow and oxygen delivery to tissues thereby causing a heart 
attack or stroke. While there are several known risk factors and behaviors that increase 
the likelihood of developing atherosclerosis, the underlying cause of the disease remains 
unknown.  
 MicroRNAs have emerged as key regulators of cell phenotypes and diseases. 
Furthermore, multiple miRNAs have emerged to play a role in atherosclerosis. In fact, 
multiple studies have been undertaken to study the role of mechanosensitive miRNAs in 
atherosclerosis (Ch. 1.6.2). However, prior to this project, there were no studies on miR-
744 in ECs, its regulation by mechanical forces generated by blood flow, or the 
investigation of miR-744 as a potential therapeutic target for atherosclerosis. Only a few 
studies have used target site blocker technology (Ch 1.6.5), and this is the first to show the 
blockage of a specific miRNA-target interaction (744-LIMS2) by target site blockers is 
sufficient to reduce atherosclerotic plaques in a d-flow-induced model of atherosclerosis. 
Finally, this work may lead to a new therapy to help prevent CVD. 
 Rationale 
 Although miR-663 may be an important mediator of endothelial inflammation in 
humans, given that miR-663 is not broadly conserved, future studies of miR-663 as a 
therapeutic target are limited. Fortunately, we identified miR-744 as a homolog of miR-
663 which is broadly conserved in mammalian species. In the literature, miR-744 plays a 
role in a variety of diseases in both humans and mice, however, the role of miR-744 in 
endothelial biology or cardiovascular disease is unknown. Preliminary results established 
38 
 
significant miR-744 upregulation in ECs under OS in vitro in both human ECs and mouse 
ECs. Furthermore, it was established that miR-744 plays a significant role in monocyte 
adhesion and endothelial inflammation in human cells in vitro, which is a key precipitating 
event in d-flow-induced atherosclerosis development. Therefore, the role of miR-744 in 
endothelial inflammation was investigated in Aim I. 
 The functional role of miR-744 is to bind to target mRNAs and thus suppress target 
translation. In Aim 2, the mRNA transcripts being loaded on the RISC complex under miR-
744 overexpression in vitro were compared to mRNA transcripts which are depleted in d-
flow in vivo from the partial carotid ligation microarray and a network of genes that change 
due to miR-744 was discovered. However, ultimately, LIMS2 was discovered to be the 
most consistent target of miR-744. To implicate miR-744 specifically in d-flow-induced 
suppression of LIMS2, the effect of miR-744 modulation on LIMS2 was tested in vitro and 
in vivo in Aim 3. 
 Innovation 
 The finding that miRNAs are induced by disturbed blood flow is relatively recent, 
and is supported by both in vitro studies in ECs and limited in vivo studies. However, the 
mechanisms by which miRNAs can lead to atherosclerosis are still not fully described. 
Although some miRNAs have already been implicated in atherosclerosis, there have been 
no previous studies of miR-744 in ECs and atherosclerosis. As a result of a lack of research 
surrounding miR-744 in ECs, investigation of gene change and functional changes with 
antimiR-744 or miR-744 mimics has not been previously attempted in this cell type. 
Modulation of miR-744 in vitro has provided important insight into the role miR-744 plays 
in EC inflammation. Results from in vitro studies indicate that there is a functional effect 
of miR-744 inhibition on EC inflammation. However, our in vivo model of acute d-flow-
induced atherosclerosis has indicated that the interaction of miR-744 specifically with 
LIMS2 may be a novel therapeutic target for atherosclerosis. 
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 Furthermore, although our lab has generated both miRNA arrays and mRNA 
microarrays from HUVECs subjected to LS or OS and from our mouse model of d-flow-
induced atherosclerosis, these datasets have not yet been fully integrated with a specific 
focus on known mediators of EC processes. Additionally, with RNA sequencing 
information to inform us of the direct targets of miR-744 in HUVECs, the proposed study 
will be the first to identify a full network of targets of a miRNA. This work has identified 
a novel target of miR-744 and established its relevance to EC inflammation and 
atherosclerosis.  
 Project Objective 
 While we know that laminar, unidirectional flow upregulates “atheroprotective” 
genes and downregulates “pro-atherogenic” genes while disturbed, reversing, or stagnant 
flow results in the opposite phenomenon, the mechanism by which flow controls EC gene 
expression is unknown. The goal of this project was to determine how the miR-744 
responds to flow, causes altered gene expression, and regulates 
atherosclerosis development. 
 Overall Hypothesis 
Disturbed flow increases miR-744 expression in endothelial cells. This in turn causes a 
downregulation of key target genes such as LIMS2 in ECs, which ultimately initiates the 








 Specific Aim I: Demonstrate the Mechanosensitivity of                                 
miR-744 and Its Role in EC Inflammation 
 We initially discovered miR-744 through its homology with another miRNA miR-
663. In Aim I, we validated that miR-744 is upregulated by OS in human endothelial cells 
like its sister miRNA. Furthermore, we found that miR-744 is also robustly expressed in 
mice and is upregulated by OS in mouse endothelial cells and in endothelial RNA derived 
from a murine model of d-flow-induced atherosclerosis (partial carotid ligation) and in the 
chronically flow disturbed lesser curvature (LC). Subsequently, in order to further 
investigate the role of miR-744 in OS-induced inflammation, its effect on monocyte 
adhesion and inflammatory marker expression (ICAM1, VCAM1, and MCP-1) were 
assessed under conditions of miRNA overexpression via miRNA mimics and inhibition 
via locked nucleic acid (LNA) complementary antimiRNAs respectively. We found that 
treatment with mimics increased monocyte adhesion and ICAM1/VCAM1/MCP-1 mRNA 
expression even in anti-inflammatory LS conditions. Furthermore, we found that p65 
protein expression were increased by mimic treatment. Alternatively, we found that 
antimiR treatment under OS conditions drastically reduced monocyte adhesion and 
ICAM1/VCAM1 mRNA expression. These results established that miR-744 plays a role 









 Specific Aim II: Determine the Direct Targets of miR-744                               
and Their Role in EC Inflammation 
 The primary mechanism of action for miRNAs is to bind to the 3’UTR of target 
genes and initiate translational repression and/or mRNA degradation. Therefore, given the 
results described in Aim I, it was critical to identify direct targets of miR-744 which 
mediate its pro-inflammatory effects in the endothelium. Therefore, in Aim II, genes that 
are directly regulated by miR-744 and are suppressed by d-flow were determined by 1) 
sequencing of RNA derived from immunoprecipitation of the Ago2 complex under 
conditions of miR-744 overexpression 2) filtering out genes which do not have miR-744 
binding sites in the human and mouse 3’UTR 3) filtering out genes which are not 
suppressed in the LCA 48 hours post ligation (from the gene array). Out of this criteria, 13 
genes emerged. From this pool, validation was conducted in vitro and in vivo to arrive at 
LIMS2. The specific validation experiments were 1) significant suppression by OS in 
HUVECs at the mRNA level 2) significant rescue of mRNA levels by antimiR-744 in OS-
treated HUVECs, and 3) significant suppression by mimic treatment in HUVECs. After 
LIMS2 emerged as the only gene that passed the validation experiments, 3’UTR luciferase 
assays were conducted on mimic and antimiR treated iMAECs in order to establish that 
LIMS2 is a conserved target in mice. After determining that LIMS2 is a valid target in both 
species, the effect of LIMS2 on endothelial inflammation was determined using siRNA 
against LIMS2 in human ECs and conducting monocyte binding assays and 
ICAM1/VCAM1 mRNA and protein expression. We found that siLIMS2 significantly 
increased monocyte adhesion and increased inflammatory marker expression. Therefore, 
these results strongly indicated that miR-744 exerts it pro-inflammatory effects on the 
endothelium through LIMS2. 
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 Specific Aim III:  Determine the Role of miR-744                                                 
in the Development of Atherosclerosis 
  Finally, we hypothesized that inhibition of the interaction between miR-744 and its 
target genes in ECs will inhibit atherosclerosis formation in vivo. Therefore, in Aim III, we 
tested the effect of global miR-744 inhibition (via antimiR-744) on the three week partial 
carotid ligation mouse model. The degree of atherosclerotic plaque formation was 
determined via gross plaque imaging and H/E staining. Furthermore, the expression of key 
targets, such as LIMS2, was determined in the liver, lung, kidney, and spleen. We found 
that global antimiR treatment did not significantly reduce plaque formation, although the 
antimiR-744 did significantly decrease miR-744 in the kidney and spleen. However, 
LIMS2 mRNA expression was only rescued in the spleen. Given that miRNAs have 
hundreds of targets and only LIMS2 emerged in human ECs as a major player, we then 
tested the effect of blocking the interaction between miR-744 and LIMS2 via target site 
blockers in the three week partial carotid ligation mouse model. Fortunately, we found that 
the plaque was significantly reduced in the LIMS2 TSB treated animals. Furthermore, 
LIMS2 mRNA expression was significantly rescued in the spleen and kidney. Given this 





CHAPTER 3 MATERIALS AND METHODS 
 
 Cell Culture and Shear Experiments 
3.1.1 HUVECs 
Human Umbilical Vein Endothelial Cells (HUVEC, Lonza CC-2519) were maintained in 
M199 (Corning 45000-378) base culture medium containing 20% Fetal Bovine Serum 
(Atlanta Biologicals S11150), 10% penicillin/streptomycin (Gibco 15070063), 10% 
glutamine (Gibco 25030081), 10% endothelial cell growth serum (cow brain extract), and 
8,000U (USP) heparin (Sigma Aldrich H3393). Cells were cultured in 100 mm dishes 
(Falcon 353003) coated with 0.1% gelatin (Sigma Aldrich G9391) for 1 hr at 37°C. Cells 
were used at Passages 5-7 for experiments. 
3.1.2 HAECs 
Human Aortic Endothelial Cells (HAEC, Lonza CC-2535) were maintained in EGM™-2 
BulletKit (CC-3162), which contains Hydrocortisone solution, GA-1000, Fetal Bovine 
Serum SDS attached, Human Fibroblast Growth Factor basic (hFGFb), Human Vascular 
Endothelial Growth Factor (hVEGF), Analog of Human Insulin-Like Growth Factor-1 
(Long R3-IGF-1), Ascorbic Acid Solution, Human Epidermal Growth Factor (hEGF), and 
Heparin. Cells were cultured in 100 mm dishes (Falcon 353003) coated with 0.1% gelatin 








immortalized Mouse Aortic Endothelial Cells (iMAECs) were generated as described 
[352] and maintained in low glucose DMEM (Corning 45000-332) base culture medium 
containing 10% penicillin/streptomycin (Gibco 15070063), 10% endothelial cell growth 
serum (cow brain extract), and MEM Non-Essential Amino Acids (MNEAA) (Thermo 
Fisher 11140). Cells were cultured in 100 mm dishes (Falcon 353003) coated with 0.1% 
gelatin (Sigma Aldrich G9391) for 1 hr at 37°C. Cells were used within 3 passages of 
thawing for experiments. 
3.1.4 Cone and Plate Viscometer 
Briefly, cells were cultured to 100% confluency and then subjected to shear stress in the 
cone and plate viscometer for 24 Hr. Cells subjected to LS experienced a unidirectional 
shear stress of 15 dyn/cm2, whereas cells subjected to OS experienced an oscillating shear 
stress of 5 dyn/cm2. Alignment of ECs under LS was visually confirmed by microscopy. 
Cells were scraped in 600 µL HBSS (Corning 45000-462) and pelleted by centrifugation 
at 5000 rpm for 1 minute. One quarter was resuspended with Qiazol (Qiagen 79306) and 
the rest was resuspended in phosphate-buffered RIPA with glycerol (Boston Bioproducts 
BP-421) and protease inhibitor (Sigma Aldrich 11697498001).  
 




 Partial Carotid Ligation and Lesser Curvature Endothelial RNA Isolation 
3.2.1 Partial Carotid Ligation and Endothelial Flushing 
8-week-old C57BL/6 mice (Jackson Laboratories) were used for all animal studies 
according to the approved Institutional Animal Care and Use Committee protocol by 
Emory University. Mice were partially ligated under 2% isoflurane anesthesia and the 
resultant disturbed flow conditions in the LCA were determined by ultrasound (Vevo770, 
Visualsonics) with a 30-MHz probe as described previously [83].  
Briefly, 3 out of 4 caudal branches of the LCA (left external carotid, internal carotid, and 
occipital artery) were ligated with 6-0 silk suture, while the superior thyroid artery was left 
intact (Figure 1.3E). Mice were sacrificed by CO2 inhalation and were subsequently 
perfused with saline containing heparin for 5 minutes. Total carotid intimal RNA was 
isolated 48 hours later by flushing the RCA and LCA with 150 µL Qiazol, by our method 
that we have demonstrated to be endothelial-enriched without any significant 
contamination of smooth muscle cells and leukocytes [36, 83, 353]. 
3.2.2 Lesser Curvature and Greater Curvature Endothelial RNA Isolation 
8-week-old C57BL/6 mice (Jackson Laboratories) were used for all animal studies 
according to the approved Institutional Animal Care and Use Committee protocol by 
Emory University. Mice were sacrificed by CO2 inhalation and were subsequently perfused 
with saline containing heparin for 5 minutes The lesser curvature (LC) of the aortic arch 
and the thoracic aorta (TA) were isolated 48 hours later in HBSS and opened en face. The 
endothelium was placed against a nitrocellulose-membrane soaked in isopropanol for 5 
minutes, and the media and adventitia were peeled away leaving the endothelial monolayer 
adherent to the nitrocellulose membrane and RNA was extracted using Qiagen miREasy 








Figure 3.2 The Lesser Curvature is Chronically Flow-Disturbed 
 
 Quantitative real-time PCR (qPCR) Validation of miR-744 
Total RNA was purified by the Qiagen miRNeasy Kit (217004), and reverse-transcribed 
into cDNA using the Qiagen miScript II Reverse Transcriptase Kit (218161).  The resulting 
cDNA was subjected to qPCR using the Qiagen mature hsa-miR-744-5p 
(MIMAT0004945: 5'UGCGGGGCUAGGGCUAACAGC3’ MS00010549) or RNU6b 
(218193) as the forward primer and Universal Primer (218193) as the reverse primer, 
SYBR Master Mix (ThermoFisher 4472903), and the ABI StepOne Plus qPCR machine. 
The PCR conditions were 95°C, 15 min, followed by 40 cycles of 94°C, 15 s; 55°C, 30 s, 
and 70°C, 30 s. RNU6B was used as a housekeeping control. Fold changes between 







 Transfection of Nucleic Acids 
 Briefly, HUVECs were plated in 100 mm dishes and 24 hr later, the cells were transfected 
with either antimiR-744 (Exiqon LNA Power Inhibitor 4100792) or miR-744 mimic 
(miRVana 4464066) for inhibition and overexpression respectively. 1 mL of 
oligonucleotide/Oligofectamine (Invitrogen 12252011) mixture in Opti-MEM media 
(Gibco 31985070) were added to 4 mL of OPTIMEM in the plate for final dosages of 100 
nM for antimiR-744 or 40 nM miR-744 for mimic. Four hours after transfection, the media 
was replaced with standard HUVEC media. Cells treated with antimiR were immediately 
subjected to OS, but cells treated with miR-744 mimics were subject to LS 24 hr post-
transfection to allow for processing into mature miRNA. A non-target “scrambled” double-
stranded RNA (Ambion pre-miR-control) was used as a control in mimic experiments and 
a nontarget LNA oligonucleotide was used as a control in antimiR experiments. 
 
 Monocyte Adhesion Assay 
Following shear, cells were washed and incubated with fluorescently labeled THP-1 human 
peripheral blood mononuclear leukocytes (ATCC TIB-202) in serum-free media at 37°C 
for 30 minutes. THP-1 cells were labeled with 5 µL of BCECF-AM (1mg/ml, Molecular 
Probes  B1150) at 37°C for 30 minutes. 500,000 THP-1 cells were added per dish in a 
volume of 5 mL. Non-adherent THP-1 cells were be washed away with and bound cells 
will be fixed with 4% paraformaldehyde (Sigma Aldrich) and visualized by fluorescent 







 qPCR for Inflammatory Markers 
Total RNA was purified using the Qiagen miREasy kit and reverse transcribed for use in a 
two-step qRT-PCR using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems 4368814). The resulting cDNA was subjected to qPCR using the primers in 
Table 3.1, SYBR Master Mix (ThermoFisher 4472903), and the ABI StepOne Plus qPCR 
machine. The PCR conditions were 10 min at 95°C, followed by 40 cycles of 95°C for 5 s 
and 60°C  for 30 s. 18S was used as a housekeeping control. Fold changes between samples 
were determined for all targets using the ΔΔCt method. 
 































 BCA and Western Blotting for Inflammatory Markers 
Cell lysate was centrifuged at 12,000g for 10 minutes at 4°C to remove cell debris. The 
protein-containing supernatant was collected in a separate tube and 2.5 µL was added to a 
96 well plate. Bicinchoninic acid (BCA) was diluted 1:50 in Reagent A (Pierce 23225) and 
97.5 µL of the reagent was added to each protein-containing well. Protein standards were 
prepared by diluting bovine serum albumin (2mg/mL, Pierce 23209) to concentrations of 
0, 0.05, 0.1, 0.25, 0.5, and 0.75 mg/mL solutions. After a 30 minute incubation at 37°C, 
the absorbance was read by a microplate reader at 562 nm and a linear calibration curve 
was established. 
 
Each protein sample was diluted in 1X RIPA and 6X reducing loading dye (Boston 
Bioproducts) to achieve a total protein amount of 15 µg, then subsequently boiled at 95°C 
for 5 minutes. Proteins were electrophoresed in 1X running buffer (Tris-Glycine pH 8.8) 
using a 10% polyacrylamide gel. Following electrophoresis, the proteins were transferred 
to a polyvinylidene fluoride (PVDF) membrane (BioRad) and blocked in 5% (w/v) nonfat 
milk in Tris-Buffered Saline with 0.1% Tween (TBST) for 1 hour at room temperature. 
Membranes were incubated with the primary antibody solution (1:1000) (Table 3.2) 
overnight at 4°C. Following primary antibody exposure, the membrane was washed and 
incubated with secondary antibody (1:5000) (goat anti-rabbit or goat anti-mouse HRP, 
Santa Cruz SC-2004 or SC-2005) for 1 hour at room temperature. After washing, the 
membrane was developed using Immobilon Western Chemiluminescent HRP (EMD 






Table 3.2 List of Inflammatory Marker Antibodies 
ANTIBODY SPECIES CAT. NO. 
 
VCAM-1 ANTIBODY (H-276) Rabbit SC-8304 Santa Cruz 
ICAM-1 ANTIBODY (15.2) Mouse SC-107 Santa Cruz 
P65 NFKB ANTIBODY Rabbit 8242S Cell Signaling 
Technologies 
PHOSPHOP65 NFKB 
ANTIBODY (SER536)  
Rabbit 3033S Cell Signaling 
Technologies 
 
 P65 Staining 
Cells were seeded in 24-well plates (Corning) coated in 0.1% gelatin at a density of 50,000 
cells/mL. 24 hours later, cells were transfected with either a mimic or inhibitor of miR-744 
respectively. 24 hours after transfection, the cells were fixed in 4% paraformaldehyde and 
permeablized in 0.1% Triton X-100 (Sigma Aldrich) in PBS for 10 minutes, followed by 
blocking in 20% goat serum (Jackson ImmunoResearch, 005-000-121) in PBS for 1 hour. 
After blocking, cells were incubated with P65 (1:100 v/v) (Table 3.2) overnight at 4°C 
followed by incubation with secondary antibody (1:250 v/v) (Alexa Fluor 568 conjugated 









 Ago2 Immunoprecipitation and RNA Sequencing 
Static HUVECs were transfected with either 40 nM miR-744 mimic or control mimic and 
whole lysate was collected 24 hours later by scraping in ice cold HBSS and centrifugation 
at 500g for 2 minutes to pellet the cells. Next, the cells were lysed in RNA IP lysis buffer 
(Millipore MagnaRIP Kit). As per the manufacturer’s protocol, RNase free magnetic 
Protein G beads were incubated with RIP grade Ago2 antibody (Millipore) for 30 minutes 
rotating at room temperature, washed, and then subsequently incubated with the lysate 
overnight at 4C while rotating. Following incubation, the beads were washed and directly 
added to Qiazol. RNAs bound to RISC were purified and sequenced by the Yerkes 
Sequencing Core. Briefly, RNA was extracted from Qiazol using the Qiacube. Next, the 
RNA was prepared for sequencing using the ClonTech Library Prep. Then, the resultant 
cDNA was sequenced using the Illumina Hiseq3000 and each sample was read at 30 
million reads. After obtaining the total sequencing counts, the number of unique transcripts 
was mapped to annotated transcripts and normalized. Finally, the differential transcript 
counts for control mimics vs 744 mimics for each transcript was statistically calculated 
using the R package DESeq2. 
 Filtration Criteria 
Following sequencing, mRNAs which were differentially enriched between the control-
treated vs. mimic treated samples were determined based on a relaxed p value of 0.05. 
From this pool, the list of genes was compared to a list of conserved targets between human 
and mice generated from miRWalk. From this list, direct, EC-relevant targets were 
determined. Finally, this list was compared to genes which were significantly 
downregulated in the LCAs at the 48 hour time point in our partial carotid ligation 





 qPCR for Potential Targets 
Total RNA was purified using the Qiagen miREasy kit and reverse transcribed for use in a 
two-step qRT-PCR using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems 4368814). The resulting cDNA was subjected to qPCR using the primers in 
Table 3.3, SYBR Master Mix (ThermoFisher 4472903), and the ABI StepOne Plus qPCR 
machine. The PCR conditions were 10 min at 95°C, followed by 40 cycles of 95°C for 5 s 
and 60°C  for 30 s. 18S was used as a housekeeping control. Fold changes between samples 
were determined for all targets using the ΔΔCt method. 
 
Table 3.3 List of Primers for qPCR of Potential Target Genes 
 
FORWARD REVERSE 
H-LIMS2 GCGCATTGTCAACAGCAA TACTTCCGGCCTTCAAACTC 
M-LIMS2 CTGCTGACCGGTGCTAGG CCAAACACTCAGACATGTTGCT 
H-CYB561 CCTCTGCATGGTCATAGGC GAAGACACGGTAAACCAGCAG 
H-CST3 CGAACCACGTGTACCAAGAC TCTGGAAAGAGCAGAATGCTT 
H-ADK CATCACTGGTGACAACAGGTC TCTCCAGATCAAGATGTTTTTCC 
H-TCF7L2 GAATCGTCCCAGAGTGATGTCG TGCACTCAGCTACGACCTTTGC 
H-ANK3 AAAGGACTGCCTCAAACAGCGG CTAAGGATGCGAAGCTCTGTCG 
H-CALM1 CCAACAGAAGCTGAATTGCAGGA CAAAGACTCGGAATGCCTCACG 
H-EHD1 GCGTTTGGCAACGCTTTCCTCA ATCCGCTGCTTCTCTCCAGACA 
H-TRIB3 GCTTTGTCTTCGCTGACCGTGA CTGAGTATCTCAGGTCCCACGT 
H-PVRL3 ATTCCCGCTTGGAAATGCCCAG GCTGCTACTGTTTCATTTCCTCC 
H-KRAS TGGACGAATATGATCCAACAAT TCCCTCATTGCACTGTACTCC 
H-DLGAP4 CCTCAGCAATAGTCGCACGCTT ACTGCTCTGGACTGTGACTGAG 
H-NDRG1 ATCACCCAGCACTTTGCCGTCT GACTCCAGGAAGCATTTCAGCC 









 3’UTR Luciferase Assay 
3’UTR luciferase assays were conducted by co-transfecting iMAECs with a 500 ng of a 















Alternatively, a plasmid or with the miR-744 binding site mutated was transfected with 
(provided by Oskar Laur of the Emory Genomics Core) 100 M mimic (miRVana)  for 24 
hours, followed by collection of the media. After addition of the luciferin substrate, the 






 Immunofluorescence Staining 
Frozen sections were permeabilized in 0.1% Triton-X in PBS for 10 minutes, followed by 
blocking in either 20% donkey serum or goat serum (Jackson ImmunoResearch,005-000-
121 or 017-000-121) in PBS for 1 hour. Slides were incubated in the primary antibody 
(1:100) detailed in Table 3.4 overnight at 4°C followed by incubation with secondary 
antibody (1:250 v/v) (Alexa Fluor 568 conjugated goat anti-rabbit, goat anti-rat, or donkey 
anti-goat, Life Technologies). 
 Human Plaque De-paraffinization and Immunostaining 
Paraffin-embedded sections were provided by Giji Joseph (Dr. Robert Taylor) and graded 
according to H/E staining. Briefly, sections were deparaffinized by xylene and graded 
alcohol incubations. Following de-paraffinization, slides were either stained with 
hematoxylin and eosin for grading, or immunostained as above. 
 Partial Carotid Ligation and AntimiR-744 Injection 
12-week-old ApoE-/- mice (Jackson Laboratories) were used according to the approved 
Institutional Animal Care and Use Committee protocol by Emory University. Mice were 
pretreated twice with either 5mg/kg antimiR-744 or saline subcutaneously (s.c.) on Days 1 
and 2 pre-ligation. Then mice were partially ligated according to Figure 1.3E. and were 
fed a high fat diet for three weeks [83]. Throughout the three week period, mice were 
injected with either antimiR-744 or saline twice a week according to Figure 3.3. After 3 
weeks, the aortic trees (including the carotids) were dissected and examined by bright field 















 Oil Red O Staining 
Frozen blocks containing the carotid arteries were prepared in TissueTek and stored at -
80℃. Sections from the blocks were rinsed twice with distilled water for five minutes, 
incubated in 100% propanediol for ten minutes and incubation in 0.2% Oil Red-O solution 
for five minutes at room temperature. Slides were rinsed, mounted, and imaged on the 
Hamamatsu Nanozoomer. Oil Red O positive area (plaque area) was quantified using 
ImageJ software. 
 RNA Extraction from Organs and qPCR 
Mice were sacrificed 3 weeks after the study and the liver, lung, kidney, and spleen was 
collected from each animal. Each organ was snap-frozen in liquid nitrogen and crushed by 
mortar and pestle. After crushing, part of the fragments were placed in Qiazol and disrupted 
by metal beads in a tissue lyser (Qiagen). Total RNA was purified and reverse-transcribed 
as previously described.  The resulting cDNA was subjected to qPCR as previously 
described for miR-744. Alternatively, qPCR for LIMS2 was performed using mouse 
LIMS2 primers (Forward Primer: 5’CTGCTGACCGGTGCTAGG3’) and (Reverse 
Primer:5’CCAAACACTCAGACATGTTGCT3’). The 18S primer in Table 3.1 was used 
as a control. 
Figure 3.3 AntimiR-744 Injection Schedule 
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 Immunofluorescence Staining 
Frozen sections were permeabilized in 0.1% Triton-X in PBS for 10 minutes, followed by 
blocking in either 20% donkey serum or goat serum (Jackson ImmunoResearch,005-000-
121 or 017-000-121) in PBS for 1 hour. Slides were incubated in the primary antibody 
(1:100) detailed in Table 3.4 overnight at 4°C followed by incubation with secondary 
antibody (1:250 v/v) (Alexa Fluor 568 conjugated goat anti-rabbit, goat anti-rat, or donkey 
anti-goat, Life Technologies). 
 
 
Table 3.4 List of Antibodies for Immunostaining  
 
ANTIBODY SPECIES CAT.NO. 
 
VCAM-1 ANTIBODY (C-19) Goat SC-1504 Santa Cruz 
PECAM-1 ANTIBODY(MEC13.3) Rat 550274 BD Biosciences 
LIMS2 ANTIBODY HUMAN Rabbit bs-13650R Bioss 
LIMS2 ANTIBODY MOUSE Rabbit Provided by Chuanyue Wu [327] 
 
 Hematoxylin and Eosin Staining 
Frozen sections were stained using the American MasterTech kit. As per manufacturer’s 
protocol, slides were rinsed in running tap water for 2 minutes, incubated in Harris 
Hematoxylin for five minutes, rinsed and incubated in Differentiating solution for 1 
minute, rinsed and incubated with Bluing solution for 30 seconds, rinsed and incubated in 
70% ethanol for 1 minute, followed by direct incubation in Eosin in 1 minute. Finally, the 
slides were dehydrated in 3 changes of 100% ethanol and xylene. Slides were mounted and 




 TSB Design and Transfection 
TSBs were custom-designed by Exiqon to be complementary to the 3’UTR of mouse 
LIMS2 (5’TGCGGGTCAAGCAAGT3’)  
or a scrambled TSB (5’TGACGAGCGATAGGCT3’) was used as a control in all 
experiments. Briefly, iMAECs were seeded in 24 well plates and 24 hr later, the cells were 
transfected with either LIMS2 TSBs or scrambled TSBs. 50 µL of 
oligonucleotide/Oligofectamine (Invitrogen 12252011) mixture in Opti-MEM media 
(Gibco 31985070) were added to 200 µL of OPTIMEM in the plate for final dosages of 
400 nM. Four hours after transfection, the media was replaced with standard media. Cells 
were lysed either 24 hours later for RNA extraction and qPCR analysis or cells were lysed 
after 72 hours for protein. 
 Partial Carotid Ligation and TSB Injection 
12-week-old ApoE-/- mice (Jackson Laboratories) were used according to the approved 
Institutional Animal Care and Use Committee protocol by Emory University. Mice were 
pretreated twice with either 5mg/kg LIMS2 TSBs or scrambled TSBs subcutaneously (s.c.) 
on Days 1 and 2 pre-ligation. Then mice were partially ligated according to Figure 1.3E. 
and were fed a high fat diet for three weeks [83]. Throughout the three week period, mice 
were injected with LIMS2 TSBs or scrambled TSBs twice a week according to Figure 3.4. 
After 3 weeks, the aortic trees (including the carotids) were dissected and examined by 




Figure 3.4 LIMS2 TSB Injection Schedule 
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 Statistical Analysis 
Statistical analyses were carried out with Graph-Pad Prism (GraphPad Software). All error 
bars reported are s.e.m. unless otherwise indicated. Pairwise comparisons were performed 
using one-way Student’s t-tests. Multiple comparisons of means were performed using 
one-way analysis of variance followed by Tukey’s multiple comparison tests. Differences 





CHAPTER 4 AIM I: MIR-744 IS INDUCED BY DISTURBED 
FLOW AND INDUCES ENDOTHELIAL INFLAMMATION    
 Summary 
We initially discovered miR-744 through its seed sequence homology with another 
miRNA, miR-663. Unlike its sister miRNA, miR-744 is conserved in multiple mammalian 
species, including mice. Therefore, we initially demonstrate that miR-744 is also induced 
by OS in human endothelial cells and then expand this work into mice with the ultimate 
goal of studying this miRNA in our mouse model of atherosclerosis. Specifically, we found 
that miR-744 is induced  by OS in HUVECs, HAECs, iMAECs, endothelial enriched RNA 
from our model of d-flow-induced atherosclerosis (partial carotid ligation) and in the 
chronically flow disturbed lesser curvature (LC). Subsequently, in order to further 
investigate the role of miR-744 in OS-induced inflammation, its effect on monocyte 
adhesion and inflammatory marker expression (ICAM1, VCAM1, and MCP-1) were 
assessed under conditions of miRNA overexpression via miRNA mimics and inhibition 
via locked nucleic acid (LNA) complementary antimiRNAs respectively. We found that 
treatment with mimics increased monocyte adhesion and ICAM1/VCAM1/MCP-1 mRNA 
expression even in anti-inflammatory LS conditions. Furthermore, we found that ICAM1 
and p65 protein expression were increased by mimic treatment. Alternatively, we found 
that antimiR treatment under OS conditions drastically reduced monocyte adhesion and 
ICAM1/VCAM1 mRNA expression. Additionally, we found that the effects of miR-744 




4.2.1 miR-744 Shares a Seed Sequence with miR-663 and is Induced by OS in 
Human ECs 
In previous studies by our group, the primate-specific miRNA, miR-663, was discovered 
to be the most highly upregulated by OS in human umbilical endothelial cells (HUVECs). 
Furthermore, we found that increased levels of miR-663 correlate with increased adhesion 
of monocytes, a marker of endothelial inflammation. Despite these findings, as it is not 
conserved in mice, animal studies could not be conducted.  However, we found that another 
miRNA, miR-744, is conserved across many mammalian species (including mice) and 
shares a seed sequence with miR-663. Therefore, we initially assessed the expression of 
miR-744 in HUVECs and HAECs subjected to either OS or LS for 24 hours using miR-
663 as a control. Interestingly, miR-744 is increased in OS conditions by more than four-
fold in both cell types as compared to LS. Furthermore, miR-744 showed a greater 
magnitude of change in OS as compared to miR-663 in both cell types. These results 






Figure 4.1 miR-744 shares a seed sequence with miR-663 and is induced by OS in 
human ECs.  
A) Sequences of hsa-miR-663a, hsa-miR-744-5p, and mmu-miR-744-5p. Either (B) 
HUVECs or (C) HAECs were exposed to LS or OS for 24 hours. Following shear, RNA 
was collected for qPCR and miR-663a or miR-744 levels were measured and 




4.2.2 miR-744 is Induced by D-flow in Mouse ECs  
After this initial result, we wanted to determine whether the mechanosensitivity of miR-
744 could be replicated in mouse cells. Therefore, we subjected iMAECs to either LS or 
OS for 24 hours and discovered that miR-744 levels are increased by two-fold. These 
results indicate that miR-744 is a mechanosensitive miRNA both in human and mice ECs. 
Finally, to validate whether miR-744 is mechanosensitive in vivo, we tested miR-744 levels 
in endothelial RNA derived from our mouse model of acute d-flow-induced atherosclerosis 
(partial carotid ligation) and in the chronically flow disturbed LC. In ligated mice, miR-
744 was increased by two-fold in the flow-disturbed LCAs as compared to the RCAs 48 
hours post-ligation. Surprisingly, in the chronically flow-disturbed LC, miR-744 levels 
were more than 10 fold higher in the LC as compared to the GC. These results, taken 
together, show that miR-744 is mechanosensitive in both human and mouse endothelium 
and that miR-744 may increase over longer periods of exposure to d-flow. 
 
Figure 4.2 miR-744 is induced by D-flow in mice both in vitro and in vivo.  
(A) Schematic diagram of the cone and plate viscometer (B) iMAECs were exposed 
to LS or OS for 24 hours. Following shear, RNA was collected for qPCR and miR-
744 levels were measured and normalized to RNU6B. (n=6, *=p<0.05) (C) Schematic 
diagram of the partial carotid ligation model, in which 3 of the 4 caudal branches of 
the left common carotid artery (LCA) are ligated, while the contralateral right 
common carotid artery (RCA) remains untouched as an internal control. Also 
depicted are the naturally, chronically flow-disturbed lesser curvature (LC) and the 
unidirectional flow greater curvature (GC) (D) C57 Bl/6 mice were partially ligated 
for 48 hours and then sacrificed. Endothelial-enriched RNA was collected from the 
LCAs and RCAs of mice and miR-744 levels were measured by qPCR 48 hours post-
ligation. (n=5, *=p<0.05) (E) Unligated animals were sacrificed and endothelial-
enriched RNA was collected from the LC and GC. (n=4, 2 animals were pooled per 




4.2.3 miR-744 Modulates Endothelial Inflammation in human ECs 
Given that our previous studies on miR-663 indicated that d-flow-induced miR-663 
induces monocyte adhesion, we initially tested whether miR-744 also impacts monocyte 
adhesion. Therefore, we transfected HUVECs with a miR-744 mimic to artificially increase 
the levels of mature miR-744 and subjected the cells to LS for 24 hours. We discovered 
that the number of monocytes adhering to the normally quiescent LS-treated endothelium 
doubled, thus indicating that miR-744 may play a role in endothelial inflammation. To 
further test this hypothesis, HUVECs were treated with the miR-744 mimic, subjected to 
LS, and lysed for either RNA or protein to assess the expression of key d-flow-induced 
inflammatory markers which mediate monocyte adhesion to endothelium: VCAM1, 
ICAM1, and MCP1. We found that VCAM1 and ICAM1 were upregulated by two-fold at 
the mRNA level, whereas MCP1 was increased by more than four fold. Finally, as it has 
been well-established that the transcription factor NFkB mediates the increased 
transcription of these inflammatory markers, static cells were transfected with the mimic 
for 24 hours and then stained for the most common subunit of NFkB, p65. As NFkB 
remains in the cytosol unless activated by TNFα, the staining showed NFkB was mostly in 
the cytosol. However, treatment with miR-744 mimic increased total p65 levels by more 
than four-fold, which explains the upregulation of inflammatory markers downstream. 
Conversely, transfection of antimiR-744 before subjecting HUVECs to 24 hours of OS 
dramatically reduced d-flow-induced monocyte adhesion by more than eight-fold. 
Furthermore, VCAM1 and ICAM1 were decreased by 60% and MCP1 by 50%. Total p65 
reduction (50%) was also observed. Overall, these results indicate that miR-744 modulates 










Figure 4.3 miR-744 modulates endothelial inflammation in human ECs.  
HUVECs were transfected with (A-C) 100 nM of antimiR-744 and immediately 
subjected to OS or (D-F) 40 nM miR-744 for  24 Hr and subjected to LS. 24 Hr 
later, cells were  (A,D) incubated with monocytes for 30 min, and the number of 
adherent monocytes was determined. (n=6,*=p<0.05). (B,E) Alternatively, the cells 
were lysed at 24 Hr and RNA was collected for determination of the inflammatory 
markers VCAM1, ICAM1, and MCP-1. (n=4,*=p<0.05 (C,F) Static HAECs were 
transfected for 24 Hr, fixed, and stained for DAPI and total P65. (n=12,*=p<0.05) 




4.2.4 miR-744 Modulates Endothelial Inflammation in Mouse ECs 
Given that ultimately we wanted to test the therapeutic potential of miR-744 in our mouse 
model of atherosclerosis, we next wanted to validate that miR-744 could modulate 
endothelial inflammation in mouse ECs. Therefore, we transfected static iMAECs with 
either a miR-744 mimic or antimiR-744 to modulate miR-744 levels. We discovered that 
miR-744 mimics increased VCAM1 mRNA levels by four-fold, ICAM1 by two-fold, and 
MCP1 by eight-fold. Furthermore, total p65 levels increased by two-fold. Interestingly, 
antimiR-744 treatment did not significantly reduce the levels of VCAM1 and ICAM1, but 
MCP1 levels were significantly reduced by more than 50% and total p65 levels by more 
than 70%. Overall, this data indicates that miR-744 is functionally active in both humans 










Figure 4.4 miR-744 modulates endothelial inflammation in iMAECs.  
Static iMAECs were transfected with (A,B) 100 nM miR-744 for  24 Hr or (C,D) 400 
nM of antimiR-744 for 24 Hr. Subsequently, cells were  (A,C) lysed at 24 Hr and 
RNA was collected for determination of the inflammatory markers VCAM1, 
ICAM1, and MCP-1. (n=4,*=p<0.05) (B,D) Cells were transfected for 24 Hr, fixed, 





Prior to this work, there had been no investigation of the flow-dependent regulation 
of miR-744 and its role in endothelial biology. Through our in vitro and in vivo models of 
disturbed flow, we were able to study miR-744 modulation by flow. Furthermore, miRNA 
mimics and LNA-modified antisense antimiRs allowed us to discover the functional 
consequences of miR-744 in endothelial biology. Given what was previously published 
regarding miR-663, which shares a seed sequence with miR-744, we already had an 
indication that miR-744 may also be upregulated by disturbed flow and may induce 
endothelial inflammation. We showed that miR-744 is a mechanosensitive miRNA 
induced by d-flow in vivo and OS in vitro and that miR-744 increases endothelial 
inflammation and inhibition suppresses inflammation in both human and murine ECs. 
Given its dramatic flow-sensitivity and effect on endothelial inflammation, we expect that 
miR-744 may play a key role in atherosclerosis.  
However, it would also be interesting to examine the interplay between miR-744 and 
miR-663. miR-663 is derived from the miR-663 gene on Chromosome 20 and from the 
RN45S region of ribosomal RNA, which is normally degraded by XRN1 under LS 
conditions [36], whereas miR-744 is derived from the miR-744 gene on Chromosome 17, 
overlaps with the MAP2K4 gene, and is not found in the RN45S region [313]. Given that 
miR-663 is derived from two locations, it is unsurprising that in HUVECs, miR-663 is 
expressed more than 20-fold higher than miR-744. In HAECs, miR-663 is only 5-fold 
higher in LS and three fold higher in OS. Surprisingly, both miRNAs are much higher 
expressed in HUVEC as opposed to HAEC. HUVEC expression of miR-663 is doubled 
under LS conditions, whereas miR-744 is more than 4 fold higher. However, although the 
expression of miR-744 in iMAECs is double that of HAECs, the OS levels are the same. 
This indicates that these pro-inflammatory miRNAs are basally higher in the less 
terminally differentiated HUVECs and are slightly less shear-responsive as in arterial cells 
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(HAEC and iMAEC). The difference in iMAEC versus HAEC may be explained by the 
immortalization process of the iMAECs possibly introducing basally higher levels of 
inflammation than seen in these early passage HAECs. Given that there is no difference in 
the copy numbers in OS conditions, it seems unlikely that miR-744 is more highly 
expressed in mice than human. However, future studies would be to more closely examine 
the miRNA profile in HUVEC versus HAEC, especially as HUVECs are widely used in 
vascular biology experiments to screen for miRNAs and look for phenotypic differences 












Figure 4.5 miR-663 and miR-744 copies vary in HUVECs, HAECs, and iMAECs.    
HUVECs, HAECs, or  iMAECs were exposed to LS or OS for 24 hours. Following 
shear, RNA was collected for qPCR and (A, B) miR-663 and/or (A-C) miR-744 
levels were measured in (A) HUVECs or (B) HAECs or (C) iMAECs and 




Further examination of the copy number of miR-744 in vivo reveals that the RCA 
and LCA endothelial-enriched RNA has a similar copy number to iMAECs and HAECs. 
However, miR-744 copy numbers are significantly higher in the GC and LC and in fact are 
more than 50 fold higher than the levels seen in HUVECs. As the methodology for 
collecting endothelial enriched RNA from the GC and the LC involves directly incubating 
the areas with isopropanol-soaked nitrocellulose membranes and typically gives much 
lower yield than carotid flushings, the high copy numbers may be due to false inflation 










Figure 4.6 miR-744 copies vary in the carotids and in the aortic arches of mice.  
 (A)  C57 Bl/6 mice were partially ligated for 48 hours and then sacrificed. 
Endothelial-enriched RNA was collected from the LCAs and RCAs of mice and 
miR-744 levels were measured by qPCR 48 hours post-ligation. (n=5, *=p<0.05) (B) 
Unligated animals were sacrificed and endothelial-enriched RNA was collected 
from the LC and GC. (n=4, 2 animals were pooled per sample, *=p<0.05) Data are 




Although the investigation of miR-744 in alternative cell types and among other 
endothelial cell types certainly merits further investigation, the results of this aim have also 
opened other potential avenues of investigation. Some potential future studies may be to 
investigate the role of miR-744 in other markers of EC dysfunction, such as proliferation 
[355-357]  and migration. Several studies have found that physiologically relevant shear 
stress decreases endothelial turnover by decreasing proliferation and apoptosis. 
Specifically, apoptosis is triggered by lack of shear stress [358-360].  
Furthermore, there is an increase in cell density before flow loading and endothelial 
cell proliferation increases dramatically within 48 hours after reduction of shear stress, 
whereas OS induces cell turnover. Alterations of shear stress in arteries revealed that EC 
apoptosis and cell turnover/proliferation increase significantly under low–shear stress 
conditions. It was first proposed that leaky junctions around cells in a state of apoptosis or 
mitosis provide the major pathway for transport of large molecules such as LDL across the 
endothelium [361] . More recent studies have shown a strong correlation between apoptosis 
and mitosis rates and LDL permeability of endothelial monolayers in culture [35]. 
Ultimately, chronic differences in shear stress affect LDL transport into the vessel wall and 
that low shear stress may be expected to increase LDL permeability, which is a factor in 
atherosclerosis. Furthermore, it has been found by our lab that LS inhibits EC migration 
and angiogenesis Angiogenesis also plays a role in atherosclerosis [38, 39]. Furthermore, 
miR-744 has previously been implicated in migration and proliferation (Ch. 1.7). Our 
preliminary studies reveal that in HUVECs, miR-744 mimic significantly increased 
















Figure 4.7 miR-744 modulates migration and proliferation in human ECs.  
HUVECs were transfected with (A,C) 40 nM miR-744 for  24 Hr  or (B,D) 100 nM 
of antimiR-744. 24 Hr later, cells were (A,B) scratched with a pipette tip and the 
wound was imaged in 6 places at 0, 6, and 16 hours. (n=3,*=p<0.05). (C,D) 
Alternatively, the cells were fixed at 24 Hr and stained with DAPI or Ki67. Data are 





CHAPTER 5 AIM II: MIR-744 MEDIATES ENDOTHELIAL 
INFLAMMATION VIA LIMS2 
 Summary 
 Next, we wanted to determine the mechanism by which miR-744 could induce 
endothelial inflammation and in the process, discovered multiple novel, flow-sensitive 
genes. To accomplish this goal, we treated HUVECs with a miR-744 mimic and sequenced 
the mRNAs derived from immunoprecipitating the RNA-Induced Silencing Complex in 
order to discover functional targets of miR-744 in human ECs. We found more than 300 
mRNAs were differentially enriched in the RISC as a result of increased miR-744. From 
this pool of mRNAs, we specifically wanted to study direct targets of miR-744 that were 
conserved in humans and mice, so we filtered the pool down to 134 which are putative 
conserved direct targets. From this smaller pool, we compared this list to the genes which 
were lost in the flow-disturbed LCA at the 48 hour time point by more than 30% in our 
partial carotid ligation model and found 13 genes which were significantly downregulated. 
After arriving at this pool of genes, we subsequently screened out genes based on shear 
sensitivity and responsiveness to both anti-744 and mimic treatment in HUVECs. From the 
screening, LIMS2 emerged as a consistent target in HUVECs. Then, the shear sensitivity 
of LIMS2 was validated at the protein level in HAECs by LS/OS and at the mRNA level 
and protein level in partially ligated mice, as well as by 3’UTR luciferase assays in 
iMAECs. Furthermore, we discovered that LIMS2 expression is lost in advanced 
atherosclerotic lesions in human patients. Therefore, the functional consequences of the 
loss of LIMS2 was determined in HAECs. It was found that siLIMS2 profoundly induced 
EC inflammation by upregulating ICAM1/VCAM1/MCP-1 mRNA expression and 






5.2.1 Sequencing of Ago2-Immunoprecipitated RNAs and Sequencing Reveals 13 
Conserved Targets 
 Although there have been multiple published targets of miR-744, miRNAs can target 
hundreds of genes in a cell-type specific manner and thus it is crucial to identify targets of 
miR-744 which would be relevant to endothelial biology and atherosclerosis. Therefore, in 
order to discover these additional targets and gain a comprehensive picture of the miR-744 
regulatory network in the context of EC dysfunction and atherosclerosis, genes directly 
regulated by miR-744 were determined by sequencing RNA derived from 
immunoprecipitation of Ago2 (RISC) under conditions of miR-744 elevation. To this end, 
static HUVECs were transfected with miR-744 mimic or control mimic for 24 hours. 
Following transfection, cell lysate was collected in RNA IP lysis buffer and was incubated 
with Ago2 antibody-conjugated beads overnight. Following incubation, the beads were 
washed and directly added to Qiazol and RNAs bound to RISC were purified and 
sequenced by the Yerkes Sequencing Core. Genes which were enriched in the sequencing 
were compared to predicted targets and our previously published mouse endothelial gene 
array data to reveal 13 potential targets. On first pass, more than 800 genes were 
differentially increased or decreased in the RISC in the mimic-treated vs. the control 
treated. After filtering out transcripts with less than 100 reads, more than 300 transcripts 
were enriched in the 744 treated, meaning they could be potential targets. This pool of 
genes was compared to a list of potential targets of miR-744, meaning they have a binding 
sequence for miR-744 in the 3’UTR in both the human and mouse isoforms. From these, 
more than 100 transcripts could be conserved targets of mIR-744 in ECs. Finally, to obtain 
potentially mechanosensitive targets of miR-744, this list was compared to genes which 
were decreased in the LCAs of partially ligated mice 48 hours post-ligation by at least 30%. 
Of these, 13 genes emerged which were decreased in the LCAs, potential conserved targets, 
























Figure 5.1 RNA Sequencing Reveals 13 Potential miR-744 Targets.  
Static HUVECs were transfected with either 40 nM miR-744 or control mimic for 
24 Hr, followed by Ago2 immunoprecipitation and sequencing of the resultant 
mRNAs. Genes which were enriched in the IP were compared to the miRWalk 
database of predicted targets in humans and mice, and the genes which were also 
downregulated at 48 Hr in the flow-disturbed LCAs of our previously-published 
mouse model (Ni et al Blood 2010) were selected for further analysis. (B) Fold 
change in the mRNA array (n=5) (C) Fold change in the RNA Seq data (n=3) 




5.2.2 Target Screening Reveals LIMS2 is a mechanosensitive target of miR-744 in 
HUVECs 
 Initially, the mechanosensitivity of the 13 genes identified by RNA sequencing were 
validated in HUVECs were exposed to LS or OS for 24 hours. Following shear, RNA was 
collected for qPCR and potential targets were measured. Interesting, although all 13 genes 
change by more than 30 % in our partial carotid ligation microarray, only 9 genes were 
upregulated by LS in vitro. From the remaining genes,  cells were either transfected with 
antimiR-744 for 4 hours, followed by 24 Hr of OS, or transfected with non-targeting 
antimiR and subjected to LS or OS in order to assess responsiveness to miR-744. 
Interestingly, only five of the original 9 genes were significantly upregulated by LS, and 
three were rescued by antimiR-744. Finally, in order to validate the effect of miR-744 on 
these remaining genes, static HUVECs were transfected with 40 nM 744 mimic and RNA 
was collected 24 Hr later. Although 5 genes were responsive to the mimic, only LIMS2 





























































Figure 5.2 LIMS2 Emerges as a Consistent, Mechanosensitive Target of miR-744 in 
HUVECs. (A) HUVECs were exposed to LS and OS for 24 hours. Following shear, 
RNA was collected for qPCR and potential targets were measured. (n=3,*=p<0.05) 
(B) HUVECs were either transfected with antimiR-744 for 4 hours, followed by 24 
Hr of OS, or transfected with non-targeting antimiR and subjected to LS or OS. 
(n=3,*=p<0.05) (C) Static HUVECs were transfected with 40 nM 744 mimic and 
RNA was collected 24 Hr later (n=4,*=p<0.05) 
76 
 
5.2.3 LIMS2 Identified as Conserved Target in Humans and Mice 
After identifying LIMS2 as consistently modulated by both miR-744 mimic and antimiR, 
the mechanosensitivity of LIMS2 was validated in HAECs subjected to either 24 hours of 
LS or OS. LIMS2 was upregulated by more than 10 fold at the protein level, which is in 
agreement with the HUVEC qPCR data. Furthermore, LIMS2 sensitivity to antimiR-744 
was validated at the protein level as well in HAECs, where antimiR was able to rescue 
LIMS2 expression by more than five fold. After establishing the mechanosensitivity of 
LIMS2 in HUVECs and HAECs, we assessed the expression of LIMS2 in our acute d-flow 
model of atherosclerosis. We found that LIMS2 expression is lost in the LCAs of mice 
under d-flow, but has robust expression in the endothelium of RCAs exposed to s-flow. 
This was quantified at the mRNA level by obtaining endothelial-enriched RNA from mice 
that had been partially ligated for 48 hours. At the mRNA level, LIMS2 expression was 
more than 70% reduced in the LCAs as opposed to the RCAs. Finally, as miR-744 has 
multiple binding sites in the 3’UTR of human LIMS2 and only one in the murine LIMS2, 
a construct containing the 3’UTR of murine LIMS2 fused to a luciferase reporter was 
transfected into iMAECs in conjunction with either the miR-744 mimic or control mimics 
in order to validate that LIMS2 is a bona fide target of miR-744. Furthermore, mutant 
plasmids containing a mutated binding sequence for miR-744 were transfected as controls. 
The mimic significantly reduced the luciferase activity of the wild-type plasmid, whereas 
the mutated plasmid was unaffected by mimic treatment, as miR-744 was unable to bind 
to it. Together, these results corroborate with the HUVEC data indicating that LIMS2 is a 






















Figure 5.3 LIMS2 is a mechanosensitive, a conserved target of miR-744.  
(A) HAECs were subjected to LS or OS and protein was collected 24 Hr later (n=5, 
*=p<0.05) (B) HAECs were transfected with 100 nM antimiR-744 and subjected to 
OS . Following shear, protein was collected (n=4, *=p<0.05). (C) Static iMAECs were 
transfected with 50 nM 744 mimic and RNA was collected 24 Hr later and LIMS2 
levels were measured by qPCR. (n=6, *=p<0.05) (D) Static iMAECs were dual-
transfected with 500 ng of the LIMS2 3’UTR luciferase plasmid (or mutants) and 50 
nM 744 mimic. Media was collected 24 Hr later, incubated with luciferin, and read in 
a plate reader. (n=9, *=p<0.05)  (E,F) C57 Bl/6 mice were partially ligated for 48 hours 
and then sacrificed. Endothelial-enriched RNA was collected and LIMS2 levels were 
measured by qPCR. LIMS2 decreased by 70% in the LCA. (F) Alternatively, frozen 
sections were generated of the LCA and RCA and stained with LIMS2.  (n=5, 




5.2.4 LIMS2 is Lost in Advanced Lesions in Human Patients  
Given these results, we next wanted to ascertain whether LIMS2 also lost in human 
atherosclerotic patients. To this end, paraffin sections of right coronary arteries were 
obtained from Dr. Robert Taylor (Emory University) and stained for LIMS2. Initially, 
sections were stained with hematoxylin and eosin to assess the degree of severity. The 
sections were scored from Grades I to V. In agreement with our previous findings, LIMS2 
was completely lost in Grades IV and V, which have advanced atherosclerotic lesions. 
However, more healthy arteries had strong, endothelial-specific staining of LIMS2. Taken 




Figure 5.4 LIMS2 is lost in Atherosclerosis.  
Right Coronary Artery sections were generated and stained for (A) Hematoxylin and 








5.2.5 LIMS2 Silencing Induces Endothelial Inflammation 
 The previous results indicate that the loss of LIMS2 may drive atherosclerosis progression. 
To test this hypothesis, HAECs were treated with siLIMS2 for 48 hours, subjected to LS, 
and either subjected to monocyte adhesion assay or lysed for RNA to determine the 
expression of VCAM1, ICAM1, and MCP1. Monocyte adhesion increased by more than 
four-fold in the siLIMS2-treated group, whereas we found that VCAM1 was upregulated 
by six-fold, ICAM1 was two-fold and MCP1 was increased by three-fold. As LIMS2 is 
lost by miR-744 mimics and in atherosclerosis, these results indicate that loss of LIMS2 
can replicate the effects seen by miR-744 mimics. Furthermore, this indicates that rescuing 











Figure 5.5 LIMS2 silencing induces endothelial inflammation in human ECs. 
 HAECs were transfected with 100 nM of siLIMS2 and and subjected to LS 24 hr 
later. 24 Hr post shear, cells were (A) incubated with monocytes for 30 min, and the 
number of adherent monocytes was determined. (n=6,*=p<0.05). (B) Alternatively, 
the cells were lysed at 24 Hr and RNA was collected for determination of the 
inflammatory markers VCAM1, ICAM1, and MCP-1. LIMS2 expression was also 






The purpose of this aim was to identify the mechanism by which miR-744 mediates 
endothelial inflammation. In order to accomplish this, the scope of the study was limited 
to the identification of direct targets of miR-744 that are conserved in humans and mice, 
significantly expressed in ECs, and were previously implicated as being mechanosensitive. 
Thus, we used a combination of in silico analysis and single gene screening to identify a 
network of genes regulated by miR-744. Although more than 300 genes were significantly 
enriched in the RISC in miR-744 mimic-treated HUVECs (Appendix A.1), more than half 
of these genes were excluded from further study due to the lack of a 3’UTR miR-744 
binding sequence (miRWalk). In some genes, there was no binding site in either the mouse 
or human 3’UTR, such as KLF2, whereas other genes did not have a binding site in either 
the human (SIRT1) or mouse (MAP1LC3B). Although these genes may be regulated by 
miR-744, we chose to focus on those that are canonically regulated by miRNA binding to 
the 3’UTR. However, in the future, studies could be conducted to study miR-744 binding 
and regulation in other areas of the transcript, such as the coding sequence region. Among 
the remaining 130 genes, 90% were eliminated upon comparison with genes which are 
downregulated in the LCAs of partially ligated mice by more than 30%. This stringent 
criteria was meant to ensure that all the genes selected for in vitro screening would be 
strongly mechanosensitive. Ultimately, less than half were consistently shear-sensitive in 
vitro (5 genes) and only one gene, LIMS2, was sensitive to both miR-744 mimic and 
antimiR-744.  
LIMS2 is a novel mechanosensitive gene that had never been studied in the 
endothelium or in the context of atherosclerosis. Given the results of Aim I, we had an 
indication that the targets of miR-744 may be protective against endothelial inflammation. 
Thus, in agreement with this hypothesis, we found that LIMS2 is a conserved target of 
miR-744 in both humans and mice and that modulation of LIMS2 replicates the effects of 
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miR-744 on endothelial inflammation. Furthermore, we found that LIMS2 is lost in the 
flow-disturbed LCA in our PCL model, which validates our array data. Finally, we found 
that LIMS2 is lost in late stage atherosclerotic patients, which indicates the importance of 
this gene to atherosclerosis progression,  
Interestingly, genes that were originally filtered out were later found to be connected 
to LIMS2, notably HIC-5. HIC-5, also known as TGFB1I1, is a LIM-domain containing 
protein family member which is also a cytoskeletal-associated protein localized to focal 
adhesion complexes with ILK and LIMS2. (Ch.1.9) HIC-5 was also the most differentially 
enriched on the RISC in our sequencing data. Also, ZYX, another cytoskeletal/focal 
adhesion protein which failed the validation studies, has been shown to localize to focal 
adhesions with ILK. (Ch.1.9). A preliminary investigation into this phenomenon reveals 
that in fact, there are multiple genes which are predicted targets of miR-744 and are 
cytoskeletal-associated proteins (Appendix A.2).  Overall, the fact that miR-744 is 
associated with multiple members of the focal adhesion complex and many general 
cytoskeletal proteins, which may be direct mechanosensors (Ch. 1.5), indicates that miR-











Overall, in this aim we found that LIMS2 is a functionally important 
mechanosensitive target of miR-744 that plays a key role in endothelial inflammation in 
vitro and is lost in advanced atherosclerotic patients. LIMS2 was validated as a bone fide 
target of miR-744 in both human and mouse ECs and d-flow-induced suppression was 
verified at the transcript and protein level in vitro and in vivo. Finally, silencing of LIMS2 
was enough to replicate the effects of miR-744, thus indicating that LIMS2 is the key target 
of miR-744 and it has a key functional role in d-flow-induced EC dysfunction and 
atherosclerosis. However, one interesting question that arises is the differential expression 
of LIMS2 in HUVEC. In fact, HAECs, iMAECs, and the carotids have similar copies of 
LIMS2 (600, 400, and 200 copies under LS conditions), whereas HUVECs have a much 
lower copy number (50 copies in LS). This discrepancy mirrors the discrepancy observed 
in Aim I, where both miR-663 and miR-744 had much higher levels in HUVECs. This 
bolsters the hypothesis that miR-744 is a significant regulator of LIMS2 in ECs. This also 











Figure 5.6 LIMS2 Copy Number is higher in arterial endothelium.  
(A) HUVECs, HAECs, or iMAECs were exposed to LS or OS for 24 hours. Following 
shear, RNA was collected for qPCR and LIMS2 levels were measured and normalized 
to 18S.  (n=4, *=p<0.05). (B) C57 Bl/6 mice were partially ligated for 48 hours and then 
sacrificed. Endothelial-enriched RNA was collected from the LCAs and RCAs of mice 
and LIMS2 levels were measured by qPCR 48 hours post-ligation. (n=5, *=p<0.05) 
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CHAPTER 6 AIM III: TARGETING THE LIMS2-744 AXIS 
INHIBITS ATHEROSCLEROSIS PROGRESSION 
 Summary 
Finally, we wanted to determine the effect of miR-744 inhibition on a mouse model of 
acute disturbed flow induced atherosclerosis. Therefore, we initially treated partially 
ligated mice with antimiR-744 twice weekly for three weeks. After sacrificing, we found 
there was no significant difference between treated and non-treated animals. Given the 
multitude of targets of miRNAs, we subsequently decided to specifically test whether 
preventing the loss of LIMS2 due to miR-744 would prevent endothelial inflammation and 
atherosclerosis progression. Therefore we tested target site blockers, which specifically 
prevent miRNAs from binding to the 3’UTR of target genes, against the miR-744 binding 
site on the mouse LIMS2 3’UTR both in vitro and in vivo. In iMAECs, we found that the 
TSBs rescued LIMS2 expression both at the mRNA and protein levels, as well as rescued 
luciferase activity in 3’UTR luciferase assays. Furthermore, we found that TSB treatment 
decreased VCAM1 protein levels. Finally, we treated partially ligated mice with either 
LIMS2 TSBs or scrambled sequence TSBs twice weekly for three weeks. After sacrificing, 
we found that the overall plaque volume was substantially lower in LIMS2 TSB-treated 
animals, as well as the arterial diameter and structure of the artery was intact. In order to 
establish the mechanism by which LIMS2 rescue may prevent plaque progression, we 
discovered through the literature that LIMS2 can stabilize ILK, and can either compete 
with PINCH1 to bind to ILK or can compensate for PINCH1 loss. Interestingly, we found 
that loss of LIMS2 in LS could reduce ILK and PINCH1 mRNA levels, which would be 
consistent for ILK As not much is known about the PINCH1-LIMS2 interaction, this could 
be a novel finding. Furthermore, antimiR-744 rescued both PINCH1 and ILK, whereas 
mimic suppressed ILK at the protein levels. This is hypothesized to be due to the 




6.2.1 AntimiR-744 Treatment Does Not Reduce Plaque  
In order to determine the role of miR-744 in the development of atherosclerosis, we used 
our murine model of acute d-flow-induced atherosclerosis, the partial carotid ligation 
model. As ApoE-/- mice develop atherosclerosis within three weeks of surgery (in 
conjunction with a high fat diet), we assessed atherosclerosis development in the LCAs of 
our mice while treating the mice either with saline or antimiR-744 at a dosage of 5 mg/kg 
for a period of three weeks. The LCAs of the mice rapidly developed atherosclerosis within 
the allotted time frame. However, upon gross examination, the degree of plaque was not 
significantly different between the treatment groups. After sectioning and staining with Oil 
Red O to clearly the lipid laden plaque area, quantification of the plaque revealed no 


































Figure 6.1 AntimiR-744 did not reduce plaque in the acute, partial carotid ligation 
model of atherosclerosis.  
ApoE–/– mice were given 5mg/kg antimiR-744 twice before ligation and then twice a 
week for three weeks along with a high fat diet. Saline was used as a vehicle control. 
(A) Gross plaque was examined using light microscopy and quantified using 
ImageJ. (B) Frozen sections of the carotid arteries were examined by Oil Red O 
staining (scale bars: 200 μm) and plaque area quantification (mm2) was done using 
ImageJ (B) (n = 5 each, data are shown as the mean ± SEM. *P < 0.05). 
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6.2.2 AntimiR-744 Did not Rescue LIMS2 Expression in the Carotids 
After the mice were sacrificed at the end of the study, the liver, lung, kidney, and spleen 
were collected in order to determine whether miR-744 was significantly inhibited at the 
given dosage. Surprisingly, miR-744 was not significantly suppressed in the liver or lung, 
but was significantly reduced by more than 40% in the kidney and spleen. However one of 
the key target genes, LIMS2 was increased by three fold in the spleen but in no other organ. 
Furthermore, on immunostaining of the carotids, LIMS2 was not significantly rescued in 
the endothelium of the treated group. Given the previous result indicating that the plaque 
burden was not reduced in these mice, miR-744 may not have sufficiently been suppressed 





Figure 6.2 AntimiR-744 Rescued LIMS2 in the Spleen, but not in the Carotids.  
 (A,B) The liver, lung, kidney, and spleen were collected and crushed for RNA. RNA 
was collected for qPCR and (A) miR-744 levels were measured and normalized to 
RNU6B or (B) LIMS2 levels were measured and normalized to 18S (n=5, *=p<0.05) 
(C) LCAs were immunostained for PECAM1 (to denote the endothelium) or LIMS2 
for either saline or antimiR-744 treated animals. 
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6.2.3 TSBs Rescue LIMS2 and Prevent VCAM1 Expression in iMAECs 
iMAECs were transfected with either LIMS2 TSBs or scrambled TSBs in conjunction with 
either luciferase plasmids or mutant plasmids in order to demonstrate that the TSBs 
effectively and specifically target murine LIMS2. Luciferase assay results indicate that the 
luciferase activity is significantly rescued by the LIMS2 TSBs, but not the scrambled TSB. 
Furthermore, mutant plasmids which do not have a 744 targeting sequence do not 
experience a rescue in luciferase activity. Furthermore, we sought to demonstrate that the 
TSBs effect on inflammation would mirror that of siLIMS2 treatment. In fact, rescue of 
LIMS2 significantly increased LIMS2 protein but significantly decreased VCAM1 protein, 






Figure 6.3 TSBs Rescue LIMS2 and Decrease VCAM1 Expression.  
Static iMAECs were (A) dual-transfected with 500 ng of the LIMS2 3’UTR luciferase 
plasmid (or mutants) and 400 nM LIMS2 TSB or scrambled TSB. Media was 
collected 24 Hr later, incubated with luciferin, and read in a plate reader. (n=9, 
*=p<0.05) (B) Static iMAECs were transfected with TSBs for 72 hr and then protein 
was collected. Both LIMS2 and VCAM1 were immunoblotted for and GAPDH was 
used as a control (n=4, *=p<0.05) 
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6.2.4 LIMS2 TSBs Significantly Reduce Plaque Burden, Arterial Diameter, and 
VCAM1 Staining in Mice 
Given that antimiR-744 did not significantly reduce the plaque burden in partially ligated 
mice and in vitro results indicate that LIMS2 TSBs can prevent endothelial inflammation, 
we next wanted to determine whether LIMS2 TSBs could rescue LIMS2 expression and 
prevent plaque development. Therefore, we assessed atherosclerosis development in the 
LCAs of partially ligated mice while treating with either LIMS2 TSBs or scrambled TSBs 
at a dosage of 5 mg/kg for a period of three weeks. Although the LCAs of the scrambled 
TSB-treated mice rapidly developed atherosclerosis within the allotted time frame, the 
LIMS2 TSB-treated mice had overall much lower volume of plaque (greater than 50%) by 
both gross examination and by H/E staining. The arterial diameters of the mice were 45% 
smaller and the elastic lamina structure was more conserved, indicating that the TSB-
treated mice had much less outward remodeling as well. Furthermore, there was 
significantly less staining for the inflammatory marker VCAM1 in TSB-treated mice. 
Overall, this data indicates that LIMS2 TSBs can significantly reduce d-flow-induced 
























Figure 6.4 LIMS2 TSBs Significantly Reduce Plaque Burden and VCAM1 
Expression. 
 ApoE–/– mice were given 5mg/kg LIMS2 TSBs twice a week for three weeks with a 
high fat diet. Scrambled TSBs were used as a control. (A) Gross plaque was examined 
using light microscopy and quantified using ImageJ. Frozen sections of the carotid 
arteries were examined by (B) hematoxylin and eosin and the plaque area was 
quantified using ImageJ (C) or stained for VCAM1 and fluorescent intensity was 





6.2.5 LIMS2 TSBs Significantly Rescued LIMS2 Expression 
After the mice were sacrificed at the end of the study, the liver, lung, kidney, and spleen 
were collected in order to determine whether LIMS2 TSBs could significantly rescue 
LIMS2 expression. Like the miR-744 study, the liver and lung did not have significantly 
increased expression of LIMS2, but LIMS2 was rescued in the spleen by more than four 
fold. In agreement with these findings, staining for LIMS2 in the LCAs revealed 
significantly more LIMS2 in the treated vs. the scrambled TSB-treated mice. Furthermore, 
there were no differences in the body weight, blood cholesterol, HDL, LDL, or 
triglycerides between the treated groups, indicating that the LIMS2 TSBs LIMS2 TSBs 











Figure 6.5 LIMS2 TSBs significantly rescued LIMS2  
(A) The liver, lung, kidney, and spleen were collected and crushed for RNA. RNA was 
collected for qPCR and LIMS2 levels were measured and normalized to 18S (n=5, 
*=p<0.05) (B) LCAs were immunostained for LIMS2 in each animal. (C) Total blood 
serum cholesterol, triglycerides (TG), high density lipoprotein (HDL), and low 
density lipoprotein (LDL) was measured in blood collected immediately before 





6.2.6 Binding Partners ILK and PINCH1 are Shear Sensitive and Regulated by 
siLIMS2 and Mimic 
 Finally, after discovering that LIMS2 is suppressed by d-flow both in vitro and in vivo and 
that rescue of LIMS2 in an acute d-flow model of atherosclerosis can significantly reduce 
plaque area, we sought to determine the mechanism by which the loss of LIMS2 may 
promote atherosclerosis development. In the literature, LIMS2 is known to bind and 
stabilize ILK, which is a well-known mechanosensitive protein recently shown to play an 
athero-protective role. Furthermore, LIMS2 has been reported to either compete with 
PINCH1 for binding or can act as PINCH1 when PINCH1 is lost. However, when LIMS2 
would act antagonistic to PINCH1 is unknown and PINCH1 and LIMS2 have not been 
studied in the endothelium before. Therefore, we first silenced LIMS2 under LS conditions 
in order to determine what happens to PINCH1 and ILK. Both proteins are suppressed at 
the mRNA level with siRNA treatment (ILK by 50%, PINCH1 by 60%), and both are 
suppressed by OS (greater than 50%). For ILK, this aligns with previous literature. 
However, previous literature indicates that PINCH1 is increased when LIMS2 is silenced 
to compensate, thus, this is a novel finding. Lastly, we wanted to determine if miR-744 
modulation could affect ILK and PINCH1 levels, which is when LIMS2 would be lost 
physiologically. Interestingly, antimiR-744 treatment increased PINCH1 (two fold) and 
ILK (1.7 fold) levels in OS conditions and in static mimic treatment, miR-744 was able to 
suppress ILK protein levels. Taken together, these results suggest that loss of LIMS2 does 
affect its binding partners ILK and PINCH1, which would promote endothelial 

























Figure 6.6 LIMS2 Modulates ILK and PINCH1 Expression. 
HAECs were either transfected with (A) siLIMS2 for 24 hours, followed by 24 Hr of LS, 
or transfected with non-targeting siRNA and subjected to LS or OS. (B) antimiR-744 for 
4 hours, followed by 24 hours of OS or non-targeting antimiR and subject to OS or LS. 
(C) Static HUVECs were transfected for 24 hours with 40 nM miR-744 mimic and 




 The goal of this aim was to evaluate the role of the miR-744-target axis in an animal 
model of d-flow induced atherosclerosis in order to discover a novel therapeutic agent for 
the treatment of atherosclerosis. Assessing the functional outcome of miRNA modulation 
in animal studies often involve multiple variables and multiple measurable outcomes. The 
animal studies described here used a dosage and dosage scheme of antimiR-744 or LIMS2 
TSBs based upon previous studies in our group.  The endpoints of the animal studies were 
based upon quantifiable measures of atherosclerosis, such as area of the gross plaque, lipid 
and VCAM1 staining in cross sections, diameters of the artery, and degree of preservation 
of the elastic laminae. Upon observing the degree of gross plaque and lipid area, a fair 
degree of variability among the mice was observed. This is not uncommon, as the size of 
lesions is never uniform among patients either. As the animals are allowed to eat freely, 
some animals may eat more or less. Furthermore, unknown genetic differences among the 
mice may make some of the mice more predisposed towards developing larger lesions. Due 
to the significant variability within the two treatment groups, there was no difference 
between the antimiR-744-treated and the saline-treated groups. The failure of antimiR-744 
to reduce plaque burden may be due to miR-744 suppressing pro-inflammatory targets in 
other cell types which were not relevant targets in endothelial cells. This result underscores 
the importance of the miRNA-target interaction in individual cell types, as well as the need 









 Examining the expression patterns of miR-744 and LIMS2 in the animal study 
perfectly illustrates this point. Although miR-744 has been reported as being highly 
expressed in many tissues throughout the body, particularly the heart, there is clearly 
differential expression among the organs. In our animal study, the copy number of miR-
744 was 10 fold higher in the lungs than in any other organ. As this work was 
predominantly concerned with the expression of miR-744 in ECs, we have not measured 
the expression in other individual cell types. All four organs have endothelial populations, 
yet the lung is the most highly enriched in ECs. Despite the lung having the highest copies 
of miR-744, it also had the highest copies of LIMS2 as well. This may be due to the fact 
that LIMS2 could be highly expressed in other cell types where miR-744 is lower, or 












Figure 6.7 Differential expression of miR-744 and LIMS2 in organs. 
(A,B) The liver, lung, kidney, and spleen were collected and crushed for RNA. RNA 
was collected for qPCR and (A) miR-744 levels were measured and normalized to 





 Although there was also variability in the degree of plaque developed among the 
LIMS2 TSB-treated mice, every marker of plaque was significantly lower in the treated 
animals. Although these results indicate that LIMS2 TSBs may be a novel therapeutic 
option for atherosclerosis, much work is still needed to translate these findings into a clinic. 
First of all, these studies must be repeated on a larger number of animals and additional 
dosages should be explored, such as 10 or 20 mg/kg. Alternatively, the route of 
administration and/or the frequency of dosages should be optimized. Furthermore, in the 
case of humans, patients have already developed atherosclerotic lesions at the time a drug 
would be administered. Therefore, treating mice that have already developed plaques and 
assessing the degree of regression would be beneficial for evaluating whether the TSBs 
would be appropriate for clinical use. Finally, one major limitation of this study is the fact 
that LIMS2 does not have a conserved binding site in humans. Therefore, the LIMS2 TSBs 
were easy to design in mice as there is only one binding site for miR-744. Before translating 
this therapy to the clinic, in vitro studies would need to be conducted in human ECs in 
order to determine the minimum number of binding sites that would need to be protected 
in order to rescue LIMS2 expression. Another confounding factor would be to determine 
whether the miR-663 binding sites also need to be protected in humans. As this study did 
not examine the effect of miR-663 on LIMS2, future studies examining this interplay are 
crucial for translation into humans. Finally, primate studies would need to be conducted in 









CHAPTER 7 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Here, we demonstrate that disturbed blood flow regulates a conserved miRNA, miR-
744, in endothelial cells and that this miRNA modulates endothelial inflammation and 
atherosclerosis by downregulating LIMS2. Not only have we identified a novel, flow-
sensitive gene and miRNA, we are one of the first to use target site blockers as a potential 
therapeutic for atherosclerosis. Furthermore, our work advances the field of miRNA 
biology in that it underscores the importance of miRNA-target specific responses, as well 
as miRNAs targeting a family of related genes. Specifically, we found that OS induced 
expression of miR-744 in cultured human and mouse endothelial cells and that both acute 
and chronic d-flow induced miR-744 in mouse arterial endothelium. Furthermore, 
increasing the miRNA levels by miR-744 mimics increased endothelial inflammation and 
inhibition of the miRNA by antimiR-744 drastically reduced endothelial inflammation in 
both human and mouse cultured ECs.  
In order to discover the underlying mechanism governing miR-744-induced endothelial 
inflammation, we merged our existing microarray of the endothelial transcriptome from 
our partial carotid ligation model with a dataset of sequenced RNA derived from 
immunoprecipitating the RISC under conditions of miR-744 elevation in HUVECs. 
Specifically, we identified genes which were downregulated in the partially-ligated left 
carotid artery (LCA exposed to d-flow) as opposed to the right contralateral control (RCA) 
after 48 hours and compared these genes which were predicted targets of miR-744 in both 
humans and mice and were enriched in the RISC after treatment with a miR-744 mimic in 
HUVECs.  
Out of the hundreds of genes revealed in the RNA sequencing data, 13 genes were 
discovered to be significantly downregulated in the LCAs, significantly enriched in the 
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RISC post-mimic treatment, and predicted targets of miR-744. Of the 13 genes, only 5 
genes were consistently downregulated by OS in HUVECs: LIMS2, KRAS, PVRL3, 
CALM1, and NDRG1. Of these genes, only LIMS2, KRAS, and PVRL3 responded to 
antimiR-744 treatment in OS, and only LIMS2 also responded to mimic treatment. The 
results of our screening studies identified LIMS2 as a major target of miR-744 in ECs, 
which we pursued for further study.  
However, although the screening process revealed a novel target gene, it also 
uncovered phenomena which provide insight into miRNAs and endothelial biology. The 
first observation is that although all 13 genes were significantly downregulated in the LCAs 
of mice (decreased by greater than 30%), only 9 genes were significantly downregulated 
in the first shear-sensitivity screen, and this number decreased to 5 (less than half), in the 
second screen. It is a well-known phenomenon that endothelial cells lose the expression of 
some genes as they are cultured over time, and the genes that were unable to be validated 
a second time may have been lost due to the later passage number of the HUVECs. 
Alternatively, there are differences in venous cells versus arterial cells, especially umbilical 
vein cells, which are not as differentiated as arterial cells. The second observation is that 
only three genes responded to antimiR treatment, whereas 5 out of 7 genes tested were 
suppressed by mimic. In general, mimic treatment introduces supraphysiological levels of 
the miRNA on the order of several hundred fold greater than the control, thus in general 
we see more effects on target gene expression and phenotypic responses with mimic 
treatment than in inhibitor treatment. Given that the effect of inhibition is dose-respondent, 
future studies using much higher dosages of the antimiR may in fact rescue the genes which 
were sensitive to mimic treatment. Finally, we observed that although KRAS, PVRL3, and 
NDRG1 were strongly mechanosensitive and responsive to either antimiR-744 or mimic 
(respectively), lack of consistent response to miR-744 excluded these genes from further 
analysis. However, given the strong mechanosensitivity of these genes and preliminary 
studies conducted on NDRG1 silencing and endothelial inflammation, these genes may 
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play a role in endothelial inflammation either in a miR-744 dependent  or independent 
manner and deserve further study. 
After identifying LIMS2 as a highly mechanosensitive gene which is also 
responsive to miR-744 mimic and antimiR-744 in HUVECs, we also validated these 
findings at the protein level in an alternative cell type, HAECs. Upon studying LIMS2, we 
found that LIMS2 is actually much more highly expressed in HAECs versus HUVECs. In 
fact, although LIMS2 mRNA levels are easily detected in HUVECs, protein expression is 
almost completely undetected except for under LS. Alternatively, miR-744 is more highly 
expressed in HUVECs versus HAECs, indicating that LIMS2 may be critical to healthy 
arterial endothelium and thus miR-744 levels are lower. Whereas in the less differentiated 
umbilical vein cells, miR-744 (and miR-663) levels are higher. Upon discovering the 
differential expression of LIMS2 in different endothelial cells, we next wanted to measure 
the expression of LIMS2 in human coronary arteries. We received sections of right 
coronary arteries and graded the sections based upon degree of plaque severity. Patients 
that had slight to moderate plaque formation (Grades I through III) had a nice robust 
expression of LIMS2, whereas LIMS2 was lost in advanced plaques. Given that disturbed 
flow is a well-established initiating factor of plaque formation, the loss of LIMS2 was 
completely in line with our observations that LIMS2 is lost in HUVECs exposed to OS or 
when treated with OS-induced miR-744.  
Although these experiments established the mechanosensitivity of LIMS2 in 
cultured ECs and its relevance in human atherosclerosis, it was necessary to directly 
implicate the loss of LIMS2 in a d-flow induced model of atherosclerosis. Thus, we carried 
out LIMS2 staining and qPCR on endothelial RNA flushings in C57 mice that had been 
ligated in the LCAs for 48 hours. As expected, we found significant loss of LIMS2 at both 
the mRNA and protein levels in the LCAs. Finally, in order to establish LIMS2 as a direct 
target of miR-744 in mice, a luciferase plasmid encoding either wild-type or a mutated 
3’UTR of mouse LIMS2 was co-transfected with either miR-744 mimic or control in 
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iMAECs . This luciferase assay confirmed that LIMS2 is a viable target of miR-744 in 
mice. Although ultimately the main concern is the interaction of miR-744 and its targets, 
such as LIMS2, are in endothelial cells, given that we would be testing LIMS2 in our mouse 
model of atherosclerosis, it was necessary to ensure that LIMS2 would be a viable target 
in mice. Furthermore, one practical constraint was that although the human 3’UTR of 
LIMS2 contains multiple binding sites for miR-744, the murine 3’UTR only contains one 
binding site, thus necessitating the mutation of only one binding site for the luciferase 
assay. The fact that LIMS2 has multiple binding sites for miR-744 (and miR-663) in 
humans as opposed to just one site in mice may indicate that LIMS2 is strongly regulated 
by both miRNAs in human cells and is regulated in conjunction with other miRNAs in 
mice. In fact, other shear-sensitive miRNAs may be regulating LIMS2 as well in 
conjunction with miR-744 and thus one future direction may be to study other miRNAs 
which are interacting with miR-744. In any case, as LIMS2 is so strongly suppressed in 
both human and murine atherosclerosis, it is quite likely that other mechanosensitive 
miRNAs may be regulating the gene as well. 
Following the identification of LIMS2, we wanted to establish that LIMS2 was a 
critical mediator of the inflammatory effects of miR-744. Therefore, we used both a 
silencing approach and rescue approach to study the effects of LIMS2 modulation on 
endothelial inflammation. Initially, we silenced LIMS2 in HAECs, where LIMS2 is highly 
expressed, and found significantly elevated endothelial inflammation. Silencing LIMS2 via 
siRNA exactly mirrored the same effects previously observed by miR-744 mimic 
treatment. However, to directly establish a causal effect between miR-744, LIMS2 
silencing, and endothelial inflammation, we treated iMAECs with target site blockers 
designed specifically to block miR-744 from binding to the 3’UTR of LIMS2 and found 
significant blunting of endothelial inflammation. LIMS2 protection by the TSBs was 
confirmed by luciferase assay and by LIMS2 protein expression. 
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Upon establishing a direct link between miR-744, LIMS2, and endothelial 
inflammation, subsequent experiments were carried out to assess the role of miR-744 and 
LIMS2 directly in our model of d-flow-induced atherosclerosis. Initially, we tested the 
effect of global miR-744 inhibition on atherosclerosis by treating partially ligated mice 
with antimiR-744 twice weekly for a period of three weeks. We found that there was no 
significant reduction in plaque burden in the antimiR-744-treated group. Furthermore, we 
found that although miR-744 levels were significantly reduced in the spleen and kidney, 
LIMS2 levels were only significantly rescued in the spleen. Additionally, LIMS2 staining 
in the carotids did not reveal significant rescue of expression. Given these results, we next 
wanted to test the effect of specifically blocking the interaction between miR-744 and 
LIMS2. Therefore, after validating that our LIMS2 TSBs rescue LIMS2 expression and 
blunt endothelial inflammation in vitro, we treated partially ligated mice with either the 
LIMS2 TSBs or a scrambled sequence TSB twice weekly for three weeks. We found a 
significant reduction in gross plaque in the LIMS2 TSB-treated mice as opposed to 
scrambled TSB-treated mice. Upon internal examination, we discovered the LCAs of the 
LIMS2 TSB-treated mice to have significantly less plaque burden and the arteries 
maintained a similar size as the RCAs and retained their internal elastic laminae structure. 
Furthermore, LIMS2 was rescued in the spleen and in the carotids of the TSB-treated mice. 
Ultimately, these results indicate that preventing the loss of LIMS2 by d-flow-induced 
miR-744 blunts the process of plaque progression. In particular, protecting LIMS2 prevents 
degradation of the ECM which is a common hallmark of atherosclerosis.  
The discrepancy between the antimiR-744 treatment and the LIMS2 TSB treatment 
may be explained by miRNA biology. As miRNAs target hundreds of genes, not all genes 
will act in concert. In fact, it is the balance of anti-inflammatory versus pro-inflammatory 
genes which will ultimately govern the response to a miRNA. Furthermore, this simplistic 
balance equation is further complicated by the fact that the miRNA may have preferential 
targets in certain cell types, so simply looking at a list of predicted targets and calculating 
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the balance will not be sufficient to predict the response. To even further complicate 
matters, specific target genes themselves may be pro-inflammatory in one cell type and 
anti-inflammatory in another. As an example, miR-744’s sister miRNA, miR-663, has been 
indicated to be anti-inflammatory in smooth muscle cells by targeting the transcription 
factors JunB and JunD [362]. However, miR-663 was strongly pro-inflammatory in 
endothelial cells in previous studies carried out by our group. Upon further examination, 
we discovered that JunB and JunD were not consistently regulated by miR-663 in 
endothelial cells (unpublished results). Therefore, global inhibition of miR-663, which 
would affect not only the endothelium but SMCs and monocytes, could very well be anti-
inflammatory. This stresses the need for more targeted delivery approaches in the future to 
specific cell types, such as the endothelium. Thus, the antimiR-744 may have allowed the 
rescue of an undesirable target gene in SMCs or in monocytes. However, in the case of the 
LIMS2 TSBs, the specific rescue of LIMS2 may be anti-atherosclerotic in both the 
endothelium and in other cell types. Our studies in Aim II have indicated that rescue of 
LIMS2 is strongly anti-inflammatory in cultured ECs. However, the previous literature 
indicates that LIMS2 is anti-migratory in SMCs [342], thus, LIMS2 TSBs may also be 
acting on the SMCs in the arterial wall as well and contributing to the anti-atherosclerotic 
effect. 
Finally, although the work described here firmly establishes the link between 
disturbed flow, miR-744, LIMS2, and atherosclerosis and thus explains how LIMS2 is lost 
in atherosclerosis, preliminary studies have been conducted in order to further investigate 
how the loss of LIMS2 contributes to atherosclerosis. The only known literature regarding 
LIMS2 indicates that the biological function of LIMS2 is to compete with LIMS1/PINCH1 
to bind and stabilize the focal adhesion protein ILK and prevent cell migration (Ch.1.8). 
Thus, as a first step in identifying the role of LIMS2 in endothelial biology, PINCH1 and 
ILK mRNA levels were measured under shear conditions in HAECs after silencing LIMS2. 
Both proteins were suppressed by OS and by LIMS2 silencing, which is consistent for ILK, 
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but seemingly contradictory for PINCH1. PINCH1 has previously been indicated to 
increase as a compensatory mechanism for the loss of LIMS2 (Ch.1.8). However, as 
PINCH1 and LIMS2 have never been studied under shear or in the endothelium, this is an 
interesting finding that merits further pursuit. Furthermore, PINCH1 and ILK mRNA 
levels were measured under shear with antimiR-744 treatment, which is a condition that 
rescues LIMS2. ILK and PINCH1 were rescued by antimiR-744 treatment, in agreement 
with the siRNA results. Furthermore, ILK protein expression was significantly reduced by 
miR-744 mimic treatment, which would mimic LIMS2 silencing. Previous reports have 
indicated that ILK is a strongly mechanosensitive protein which is degraded by ROS in 
atherosclerotic conditions and that under healthy conditions, ILK binds to eNOS in 
conjunction with Hsp90 and prevents ROS production (Ch.1.9). LIMS2 may be mediating 
its anti-inflammatory, anti-atherosclerotic effects via an ILK/eNOS-dependent pathway. 
However, future studies are needed to fully investigate the interaction of LIMS2, ILK, and 
eNOS under shear and directly implicate this mechanism is involved in preventing NFkB 
transcription of pro-inflammatory genes. These studies would most likely include more in 
depth assessment of eNOS activity and ROS production with miR-744 modulation and co-
immunoprecipitation of these protein complexes. Furthermore, as both eNOS and ILK are 
predicted targets of miR-744 (miRWalk), this raises interesting questions as to the 
interconnectedness of miRNA target gene networks and the investigation of primary vs 
secondary targets in the network.  
Throughout the course of these studies, a variety of robust experimental strategies 
were implemented, including an in vitro model of shear stress using different endothelial 
cell types, and an in vivo model of low shear-induced atherosclerosis. Furthermore, 
multiple methodologies of manipulating miRNA levels and gene levels were used in order 
to ensure that the observed phenomena could be replicated using different approaches. The 
findings by our group and others reveal that miRNAs are key regulatory elements in 




Although the scope of this project was limited to the in-depth study of one specific 
gene in the development of atherosclerosis, this project revealed that miRNAs may regulate 
a network of related genes, which has not previously been discussed (Appendix A.2). In 
fact, because the approaches used here are confined by the availabilities of technology, 
there were a variety of limitations throughout the study. One such limitation was cost 
constraints of sequencing RNA from multiple treatments, such as mimic treatment in 
iMAECs and mimic or antimiR treatment under shear conditions, or even endothelial-
enriched RNA from antimiR-744 treated mice. Integration of these datasets would have 
provided a more complete, physiologically relevant picture of the miR-744 regulatory 
network. Furthermore, studying the interplay of the miR-744 regulatory network itself was 
limited due to the sheer number of genes which are potentially regulated by miR-744. In 
fact, our defined threshold for excluding genes was meant to provide a manageable set of 
genes for screening. Yet, relaxing the stringencies would result in more target genes for 
additional studies. 
Additionally, the interplay between miR-744 and other miRNAs was not 
investigated due to the vast scope it would impose on the study. However, there are 
computational tools that can identify enriched miRNA seed motifs in lists of genes. Such 
tools could be used to find if the genes enriched in the RISC from miR-744 treatment also 
are targets of another group of common miRNAs, indicating they may act in concert with 
miR-744. Canonically, miRNAs bind to the 3’UTR of genes while on the RISC and 
facilitate their degradation (Ch.1.6). Given that this study was meant to uncover the 
molecular mechanisms of miR-744 in endothelial inflammation for the purposes of 
identifying therapeutic targets, this study did not closely examine the genes which were 
enriched on the RISC but were not predicted targets of miR-744 nor the genes which were 
depleted on the RISC with miR-744 mimic treatment.  
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Genes which were significantly depleted in the RISC may be pro-inflammatory 
genes which are the targets of anti-inflammatory miRNAs. As there were many genes 
which were enriched in the RISC but were not predicted targets of miR-744, such as KLF2, 
it would be interesting to investigate what are the miRNAs targeting these genes to the 
RISC under conditions of miR-744 elevation (Appendix A.1). An additional limitation in 
the RNA sequencing data was the fact that the library preparation was carried out using 
polyA enrichment, thus miRNAs loaded on the RISC were unable to be identified. In future 
studies, having both the miRNAs and mRNAs identified in the sample may provide a rich 
dataset to aid in these miRNA interactions. 
One overarching limitation in this study is the inherent variability in biological 
samples and in animals. This ranges from batch-to-batch variation in cells, 
mimic/antimiR/siRNA reagents, and in the individual animals used in atherosclerosis 
studies. Even the microarray platforms experience variation, such as in the dye labeling, 
efficiency in RNA, amplification and reverse transcription, and hybridization. To address 
this to the best of our abilities, multiple biological replicates or animals are used in each 
study and quality control are performed as well. 
The tools used in this study, such as the miR-744 mimic and antimiR-744, were 
specific to miR-744. Furthermore, the LIMS2 TSBs were specific to the interaction of miR-
744 with LIMS2 in mice. Thus, the LIMS2 TSBs are the most specific in terms of future 
therapeutic strategies. Despite the fact there are multiple studies using miRNAs in animals 
and there are multiple miRNA clinical trials in use, no clinical trials using TSBs have been 
initiated. The LIMS2 TSBs may be a viable new therapeutic for CVD. However, one 
limitation of this study was that the dosage of the LIMS2 TSBs in the animal studies was 
not optimized due to the availability of the TSBs. Therefore, higher dosages of TSBs may 
have more significantly inhibited plaque progression. Furthermore, the dosing schedule 
was not optimized due to the availability of the TSBs. Future studies are needed to optimize 
the dosage, route of administration, and delivery vehicle for specific targeting of the 
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endothelium. Future studies are also needed to study the effect of miR-744 and LIMS2 in 
alternative cell types, including SMCs and monocytes. 
 because atherosclerosis is a systemic disease caused by multi-cell type dysfunctions.  
 Conclusions 
The study presented here is the first to demonstrate that miR-744 and LIMS2 are 
regulated by flow, LIMS2 is lost in human and mouse atherosclerotic plaques, and that 
miR-744 targets LIMS2. We propose that d-flow induces miR-744 in endothelial cells, 
which in turn targets LIMS2 to the RISC, and the loss of LIMS2 facilitates the 
destabilization of ILK and eNOS, ultimately leading to activation of NFkB, which initiates 
endothelial inflammation and atherosclerosis. We further propose that the rescue of LIMS2 
by blocking miR-744 from binding to its 3’UTR inhibits plaque progression. In conclusion, 
our study provides a novel insight into the mechanism by which flow regulates gene 
expression by a novel miRNA and uncovers novel genes, such as LIMS2, involved in the 
endothelial cell flow response. 
 Future Directions 
The goal of this project was to determine the role of miR-744 in endothelial 
inflammation and atherosclerosis, as well as the key target genes involved in the response. 
We show that blood flow regulates miR-744 in human and mouse ECs. Despite the fact 
that several genes were identified that merit further study as potential therapeutic and 
diagnostic candidates, LIMS2 was the most flow-sensitive and the most consistent target 
of miR-744 in humans and mice. Also, LIMS2 silencing alone replicated the effects of 
miR-744 and LIMS2 rescue alone in our mouse model was sufficient to reduce 
atherosclerotic plaques. However, the upstream mechanism controlling miR-744 is 
unknown. Interestingly, miR-663 is derived from a chromosomal location and from the 
RN45S region, where it is degraded by XRN1 under LS conditions. However, miR-744 is 
not derived from the same RN45S region nor even from the same chromosome. It is 
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interesting that two completely unrelated miRs share a similar seed sequence and have 
similar phenotypic responses. Given what was known about miR-663, this study focused 
on endothelial inflammation. However, In order to determine whether there is a further 
functional role for the miR-744 and/or LIMS2 in atherosclerosis development, additional 
markers of EC dysfunction that increase in d-flow (including inflammation, apoptosis, 
proliferation, thrombosis and cell migration) could be examined in future studies. These 
functions could be independent of LIMS2 or may be mediated through LIMS2. Other 
functions of miR-744 and LIMS2 have already been reported in other cell types, such as 
proliferation and migration, yet these have not been studied extensively in ECs in our 
studies. We have undertaken preliminary studies showing that miR-744 induces 
proliferation and migration, however, nothing has yet been conducted with direct 
modulation of LIMS2. These studies will nevertheless form the backbone of future studies 
establishing the importance of miR-744 in CVD. Taking another cue from the literature, 
miR-744 may also serve as a biomarker for atherosclerosis and CVD in the future as well. 
Our computational analyses merging our partial carotid ligation array with RNA 
sequencing data containing potential miR-744 targets were designed to ask very specific 
questions regarding mechanosensitive, conserved targets of miR-744. We addressed the 
difficulty of tackling the widely unknown disease mechanism of atherosclerosis by limiting 
the scope of our project to a specific hypothesis that the genes should be downregulated by 
d-flow, enriched in the IP, and responsive to standard doses of antimiR-744 or 744 mimic. 
The huge benefit of the data collected with our dual “omics” approach is the abundant 
potential for future analyses. For example, these datasets could be used to study other 
mechanosensitive, miR-744 sensitive genes that were screened out due to inconsistencies.  
Functional studies of miRNA patterns are complicated by the various, and often 
conflicting, reports of the role of specific changes in gene expression control. We 
considered the functional consequences of specific direct targets by our computational 
analysis as described above and by performing validation studies at the single gene level 
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in vitro using qPCR, western blotting, luciferase assays, and EC inflammation assays we 
simplified the scope of the study to just one single target, LIMS2. Follow-up animal studies 
provided confirmation that the miR-744-LIMS2 axis is a crucial part of atherosclerotic 
plaque formation, but future studies will help draw more definitive links between LIMS2, 
ILK, eNOS, and the underlying mechanisms of gene expression control and ultimately 
disease development or prevention. 
Although our current study focused on examining the role of miR-744 in vascular 
biology and disease, given what is known about miR-744 and LIMS2, our work may be 
extended to other diseases, such as cardiac hypertrophy. In fact, both LIMS2 and ILK 
mutations have been indicated to play a causal role in cardiac hypertrophy and heart failure 
(Ch.1.8). Therefore, it is crucial to understand the interplay between miR-744, LIMS2, and 
ILK not just in endothelial inflammation, but in other cell behaviors (such as migration) 
and in cell types (such as SMCs) as well. With the understanding that there is only one 
binding site on the mouse 3’UTR of LIMS2 and there are multiple binding sites in the 
human LIMS2, we foresee the major impact of this study as the identification of LIMS2 
TSBs as a potential therapeutic for CVD with modifications to the sequence used in this 
study. The results of this body of work in conjunction with future studies on miR-744, other 







A.1. List of Genes Differentially Enriched in Ago2 Immunoprecipitation 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.2. miR-744 Targets Which are Cytoskeletal-Associated Proteins 
A list of known cytoskeletal-associated proteins was obtained from Pantherdb.org and 
compared to a list of predicted miR-744 targets from miRWalk.  
Table A2. List of predicted miR-744 Targets which are cytoskeletal-associated 
proteins 
ABLIM1 ABLIM2 ABLIM3 ABTB2 ACTB 
ACTG1 ACTR1A ACTR2 ACTR3B ADD1 
ADD2 ARHGAP36 ARHGAP6 ARPC4 ARPC5 
BFSP2 BTBD1 BTBD11 BTBD2 BTBD3 
BTBD9 CALD1 CAP2 CAPG CAPZA1 
CCDC67 CFL2 CGN CGNL1 CKAP5 
CLIP1 CLIP2 CLIP4 CNN3 CORO1C 
CORO2A CORO2B CORO6 COTL1 CRIP2 
CRIP3 CSRP1 CTNNA3 CTNNB1 CTNND2 
CTTN DAAM1 DAAM2 DBNL DCTN5 
DMTN DNAL4 DNALI1 DNM1 DNM1L 
DNM2 DNM3 DSTN DYNC1I1 DYNC1LI2 
EMP2 ERMN ESPNL EVPL FBLIM1 
FCHO2 FHDC1 FHL1 FHOD3 FIGNL1 
FMNL1 FMNL3 FNBP4 FRMD4A FRMD4B 
FSCN1 GAS7 GFAP GSG1L GSN 
HCLS1 HIP1 IFT57 JUP KIF11 
KIF13A KIF14 KIF17 KIF1A KIF1B 
KIF1C KIF21A KIF21B KIF24 KIF26A 
KIF3B KIF3C KIF5C KLHL11 KPRP 
KRT1 KRT2 KRT20 KRT25 KRT6B 
KRT71 KRT73 KRT76 KRT80 KRT81 
KRT9 LCP1 LDB3 LHX2 LHX3 
LHX5 LHX6 LIMA1 LIMCH1 LIMD2 
LIMS1 LIMS2 LMNA LMNB1 LMNB2 
LMO1 LMO7 LMOD1 LMX1B LPP 
MAP1A MAP1B MAP1S MAP7D2 MAPKAPK3 
MAPRE1 MAPRE2 MESDC1 MKNK1 MKNK2 
MLLT4 MLPH MOBP MPRIP MSN 
MTSS1 MTSS1L MYH10 MYH11 MYH9 
MYL6B MYO10 MYO16 MYO18A MYO1C 
MYO1D MYO1E MYO1H MYO5A MYO5B 
MYO5C MYO6 MYO9A MYO9B MYRIP 
NES NF2 NFE2L1 NUDC NUDCD3 
138 
 
ODF4 OPA1 PACSIN1 PACSIN2 PARVB 
PARVG PDE4DIP PDLIM5 PDZD7 PKP1 
PKP4 PLEK PLS3 PMP22 PPL 
PRC1 PRICKLE1 PRICKLE2 PRICKLE3 PXN 
RCSD1 RDX SDC1 SDC4 SGCD 
SGIP1 SHROOM3 SNCG SPAG16 SPAST 
SPOP SPOPL SPTB SPTBN1 SPTBN4 
STOML1 SUN1 SUN2 SYN2 SYN3 
SYNM SYNPO TBCEL TEX9 TGFB1I1/HIC5 
TLN2 TMOD1 TMOD2 TMOD3 TNNI1 
TNNT2 TPM1 TPM3 TPM4 TPPP 
TPPP3 TRIOBP TTL TTLL10 TTLL11 
TTLL12 TTLL4 TTLL5 TTLL6 TUBB2A 
TUBE1 TUBG2 TUBGCP4 TUBGCP5 TWF2 
VCL VPS4A WASF2 WASF3 WASL 
WDR1 WDR78 WIPF1 XIRP1 XIRP2 
ZBTB10 ZBTB43 ZBTB8B ZBTB9 ZFHX2 
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